pamidronate has been researched along with Bone Loss, Osteoclastic in 234 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Cyclical iv pamidronate is a widely used symptomatic therapy of osteogenesis imperfecta (OI)." | 9.12 | Pamidronate in children and adolescents with osteogenesis imperfecta: effect of treatment discontinuation. ( Glorieux, FH; Land, C; Munns, C; Rauch, F, 2006) |
| "To compare the efficacy and safety of ibandronate and pamidronate in patients with hypercalcemia of malignancy (HCM)." | 9.10 | Efficacy and safety of ibandronate in the treatment of hypercalcemia of malignancy: a randomized multicentric comparison to pamidronate. ( Bergström, B; Pecherstorfer, M; Rizzoli, R; Steinhauer, EU; Wetterwald, M, 2003) |
| " In 21 patients with breast cancer and TIO, we determined the biochemical effects of a single infusion of pamidronate given at 30 mg (n = 5), 60 mg (n = 5), 90 mg (n = 5), or 120 mg (n = 6)." | 9.08 | Intravenous pamidronate in patients with tumor-induced osteolysis: a biochemical dose-response study. ( Body, JJ; Dumon, JC; Ford, J; Piccart, M, 1995) |
| "Women with stage IV breast cancer who were receiving cytotoxic chemotherapy and had at least one lytic bone lesion were given either placebo or pamidronate (90 mg) as a two-hour intravenous infusion monthly for 12 cycles." | 9.08 | Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. ( Blayney, D; Hortobagyi, GN; Knight, RD; Lipton, A; Porter, L; Seaman, J; Simeone, JF; Sinoff, C; Theriault, RL; Wheeler, H, 1996) |
| "The superiority of pamidronate in controlling hypercalcemia is mirrored by the changes observed in these markers." | 9.08 | Evaluation of new bone resorption markers in a randomized comparison of pamidronate or clodronate for hypercalcemia of malignancy. ( Coleman, RE; Eastell, R; Guo, CY; Purohit, OP; Vinholes, J, 1997) |
| "This study was performed as a cross-sectional substudy to the Danish-Swedish Pamidronate Study, a randomized placebo-controlled multicentre trial in multiple myeloma." | 9.08 | Long-term oral pamidronate treatment inhibits osteoclastic bone resorption and bone turnover without affecting osteoblastic function in multiple myeloma. ( Abildgaard, N; Brincker, H; Brixen, K; Eriksen, EF; Glerup, H; Heickendorff, L; Kassem, M; Nielsen, JL; Rungby, J, 1998) |
| "In an uncontrolled observational study involving 30 children who were 3 to 16 years old and had severe osteogenesis imperfecta, we administered pamidronate intravenously (mean [+/-SD] dose, 6." | 9.08 | Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. ( Bishop, NJ; Chabot, G; Glorieux, FH; Lanoue, G; Plotkin, H; Travers, R, 1998) |
| "To assess the effects of 3-amino-1-hydroxypropylidine-1,1-bisphosphonate (pamidronate) in rheumatoid arthritis (RA)." | 9.07 | Clinical and biochemical response to single infusion of pamidronate in patients with active rheumatoid arthritis: a double blind placebo controlled study. ( Breedveld, FC; Dijkmans, BA; Eggelmeijer, F; Papapoulos, SE; van Paassen, HC, 1994) |
| "The improved efficacy of zoledronic acid compared with pamidronate disodium has been demonstrated in a pooled analysis of two randomized clinical trials in patients with hypercalcemia of malignancy." | 8.81 | The use of zoledronic acid, a novel, highly potent bisphosphonate, for the treatment of hypercalcemia of malignancy. ( Major, P, 2002) |
| "Pamidronate use in a CCI population is associated with reduced mortality, lower hypoglycemia rates, improved albumin, and stable renal function." | 7.83 | INTRAVENOUS PAMIDRONATE IS ASSOCIATED WITH REDUCED MORTALITY IN PATIENTS WITH CHRONIC CRITICAL ILLNESS. ( Casey, MF; Godbold, JH; Mechanick, JI; Moshier, EL; Rho, L; Schulman, RC; Zaidi, M, 2016) |
| "To verify radiomorphometric indices and fractal dimension (FD) in dental panoramic radiographs (DPRs) of children with different types of osteogenesis imperfecta (OI) and also to verify the effect of pamidronate (PAM) treatment in such panoramic analyses." | 7.83 | Dental panoramic indices and fractal dimension measurements in osteogenesis imperfecta children under pamidronate treatment. ( Acevedo, AC; Apolinário, AC; Castro, LC; de Melo, NS; de Paula, AP; de Paula, LM; de Souza Figueiredo, PT; Guimarães, AT; Leite, AF; Sindeaux, R, 2016) |
| "Zoledronic acid and pamidronate are the two bisphosphonates approved in the United States to reduce multiple myeloma skeletal complications." | 7.81 | Comparative effectiveness on survival of zoledronic acid versus pamidronate in multiple myeloma. ( Carson, K; Colditz, G; Gage, B; Luo, S; Sanfilippo, KM; Tomasson, M; Vij, R; Weilbaecher, K, 2015) |
| "In a cross-sectional study, 24-h urinary excretion of pamidronate and the biochemical marker of bone resorption N-terminal telopeptide of type 1 collagen and serum alkaline phosphatase were measured in 40 patients with bone metastases from breast cancer at the beginning, after 3-6 months, and after 1 year of treatment with intravenous pamidronate 90 mg every 3-4 weeks." | 7.73 | Skeletal retention of bisphosphonate (pamidronate) and its relation to the rate of bone resorption in patients with breast cancer and bone metastases. ( Cremers, SC; den Hartigh, J; Gelderblom, H; Papapoulos, SE; Seynaeve, C; van der Rijt, CC; van Zuylen, L; Vermeij, P, 2005) |
| "Intravenous pamidronate is widely used to treat children with moderate to severe osteogenesis imperfecta (OI)." | 7.72 | Delayed osteotomy but not fracture healing in pediatric osteogenesis imperfecta patients receiving pamidronate. ( Fassier, F; Glorieux, FH; Munns, CF; Rauch, F; Zeitlin, L, 2004) |
| "Cyclical pamidronate infusions increase bone mass in children suffering from osteogenesis imperfecta." | 7.71 | The effects of intravenous pamidronate on the bone tissue of children and adolescents with osteogenesis imperfecta. ( Glorieux, FH; Plotkin, H; Rauch, F; Travers, R, 2002) |
| " pamidronate in patients with osteoporosis." | 7.71 | A pharmacokinetic and pharmacodynamic model for intravenous bisphosphonate (pamidronate) in osteoporosis. ( Cremers, S; den, HJ; Hamdy, N; Papapoulos, S; Sparidans, R; Vermeij, P, 2002) |
| "Three children with osteogenesis imperfecta, severe osteopenia, and repeated fractures were treated with cyclic infusions of aminohydroxypropylidene bisphosphonate (pamidronate) for a period ranging from 22 to 29 months." | 7.69 | Intravenous pamidronate treatment in osteogenesis imperfecta. ( Bembi, B; Bottega, M; Ceschel, S; Ciana, G; Martini, C; Parma, A; Zanatta, M, 1997) |
| "28 patients with progressing painful bone metastases (18 breast cancer, 9 myeloma and 1 low grade lymphoma) received pamidronate 60 mg by 24 h continuous infusion for at least 2 courses (range 2-12)." | 7.68 | Treatment of bone metastases from breast cancer and myeloma with pamidronate. ( Burckhardt, P; Cornu, P; Leyvraz, S; Perey, L; Thiébaud, D; Thiébaud, S; von Fliedner, V, 1991) |
| "All patients had osteopenia, diminished osteoid formation and bone volume on histomorphometry pre-therapy with high turnover bone disease (HTO) in TM and low-turnover disease (LTO) in TI." | 6.77 | Prospective study of histomorphometry, biochemical bone markers and bone densitometric response to pamidronate in β-thalassaemia presenting with osteopenia-osteoporosis syndrome. ( Bajoria, R; Byers, M; Chatterjee, R; Davis, BA; Porter, JB; Pringle, J; Shah, FT; Sooranna, D, 2012) |
| "Osteoprotegerin (OPG) is a decoy receptor for OPG ligand (OPGL), or receptor activator of NF-kappaB ligand (RANKL)." | 6.71 | A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. ( Bekker, PJ; Body, JJ; Coleman, RE; Dunstan, CR; Facon, T; Fermand, JP; Geurs, F; Greipp, P; Harousseau, JL; Holloway, D; Lipton, A; Mariette, X; Martin, SW; Nakanishi, A; Williams, CD, 2003) |
| "Rate of bone resorption was assessed by the biochemical markers: serum carboxy terminal cross-linked telopeptide of type I collagen, urinary carboxy terminal cross-linked telopeptide of type I collagen normalized to creatinine and urinary amino-terminal telopeptide of type I collagen normalized to creatinine; and rate of cartilage degradation by urinary carboxy terminal telopeptide of type II collagen normalized to creatinine." | 6.71 | Short term whole body retention in relation to rate of bone resorption and cartilage degradation after intravenous bisphosphonate (pamidronate) in rheumatoid arthritis. ( Cremers, SC; Den Hartigh, J; Dijkmans, BA; Lems, WF; Lodder, MC; Papapoulos, SE; Van Pelt, P; Vermeij, P, 2004) |
| "Pamidronate was administered at a monthly dose of 90 mg iv, and the above parameters were evaluated at the beginning of this study and after 1, 3, 6, 9, 12 and 14 months of treatment." | 6.69 | Effect of pamidronate administration on markers of bone turnover and disease activity in multiple myeloma. ( Anargyrou, K; Meletis, J; Palermos, J; Papassavas, P; Terpos, E; Tsionos, K; Viniou, N; Yataganas, X, 2000) |
| " Oral etidronate given daily showed no clinical benefit, whereas the use of oral clodronate daily did reduce the development of new osteolytic lesions but did not significantly affect bone pain or rates of pathologic fractures." | 6.18 | Bisphosphonates in multiple myeloma. ( Berenson, JR, 1997) |
| "Alendronate is an aminobisphosphonate that acts as a potent inhibitor of osteoclastic bone resorption." | 5.29 | Alendronate distributed on bone surfaces inhibits osteoclastic bone resorption in vitro and in experimental hypercalcemia models. ( Azuma, Y; Kiyoki, M; Ohta, T; Okabe, K; Oue, Y; Sato, H; Tsuchimoto, M, 1995) |
| "Treatment with pamidronate resulted in a higher BMC of the lumbar spine than in the untreated animals, with elevated concentrations of hPTH." | 5.28 | Pamidronate reduces PTH-mediated bone loss in a gene transfer model of hyperparathyroidism in rats. ( Dobrolet, NC; Mitlak, BH; Neer, RM; Nussbaum, SR; Rodda, CP; Von Deck, MD, 1991) |
| "Cyclical iv pamidronate is a widely used symptomatic therapy of osteogenesis imperfecta (OI)." | 5.12 | Pamidronate in children and adolescents with osteogenesis imperfecta: effect of treatment discontinuation. ( Glorieux, FH; Land, C; Munns, C; Rauch, F, 2006) |
| "To compare the efficacy and safety of ibandronate and pamidronate in patients with hypercalcemia of malignancy (HCM)." | 5.10 | Efficacy and safety of ibandronate in the treatment of hypercalcemia of malignancy: a randomized multicentric comparison to pamidronate. ( Bergström, B; Pecherstorfer, M; Rizzoli, R; Steinhauer, EU; Wetterwald, M, 2003) |
| "In the first year of treatment monthly intravenous pamidronate administration as an adjunct to chemotherapy in patients with advanced multiple myeloma with osteolysis is an efficient approach in prevention and treatment of hyperacalcaemia, hypercalciuria and bone pain." | 5.09 | Effect of pamidronate on skeletal morbidity in myelomatosis. Part 1. The results of the first 12 months of pamidronate therapy. ( Kraj, M; Maj, S; Nasiłowska, B; Pawlikowski, J; Pogłód, R, 2000) |
| " In 21 patients with breast cancer and TIO, we determined the biochemical effects of a single infusion of pamidronate given at 30 mg (n = 5), 60 mg (n = 5), 90 mg (n = 5), or 120 mg (n = 6)." | 5.08 | Intravenous pamidronate in patients with tumor-induced osteolysis: a biochemical dose-response study. ( Body, JJ; Dumon, JC; Ford, J; Piccart, M, 1995) |
| "Women with stage IV breast cancer who were receiving cytotoxic chemotherapy and had at least one lytic bone lesion were given either placebo or pamidronate (90 mg) as a two-hour intravenous infusion monthly for 12 cycles." | 5.08 | Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. ( Blayney, D; Hortobagyi, GN; Knight, RD; Lipton, A; Porter, L; Seaman, J; Simeone, JF; Sinoff, C; Theriault, RL; Wheeler, H, 1996) |
| "The superiority of pamidronate in controlling hypercalcemia is mirrored by the changes observed in these markers." | 5.08 | Evaluation of new bone resorption markers in a randomized comparison of pamidronate or clodronate for hypercalcemia of malignancy. ( Coleman, RE; Eastell, R; Guo, CY; Purohit, OP; Vinholes, J, 1997) |
| "This study was performed as a cross-sectional substudy to the Danish-Swedish Pamidronate Study, a randomized placebo-controlled multicentre trial in multiple myeloma." | 5.08 | Long-term oral pamidronate treatment inhibits osteoclastic bone resorption and bone turnover without affecting osteoblastic function in multiple myeloma. ( Abildgaard, N; Brincker, H; Brixen, K; Eriksen, EF; Glerup, H; Heickendorff, L; Kassem, M; Nielsen, JL; Rungby, J, 1998) |
| "In an uncontrolled observational study involving 30 children who were 3 to 16 years old and had severe osteogenesis imperfecta, we administered pamidronate intravenously (mean [+/-SD] dose, 6." | 5.08 | Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. ( Bishop, NJ; Chabot, G; Glorieux, FH; Lanoue, G; Plotkin, H; Travers, R, 1998) |
| "To assess the effects of 3-amino-1-hydroxypropylidine-1,1-bisphosphonate (pamidronate) in rheumatoid arthritis (RA)." | 5.07 | Clinical and biochemical response to single infusion of pamidronate in patients with active rheumatoid arthritis: a double blind placebo controlled study. ( Breedveld, FC; Dijkmans, BA; Eggelmeijer, F; Papapoulos, SE; van Paassen, HC, 1994) |
| "Zoledronic acid (Zometa is a third-generation nitrogen-containing parenteral bisphosphonate indicated for the treatment of bone metastases due to solid tumours or multiple myeloma and for hypercalcaemia of malignancy (HCM)." | 4.84 | Zoledronic acid: a pharmacoeconomic review of its use in the management of bone metastases. ( McKeage, K; Plosker, GL, 2008) |
| "The improved efficacy of zoledronic acid compared with pamidronate disodium has been demonstrated in a pooled analysis of two randomized clinical trials in patients with hypercalcemia of malignancy." | 4.81 | The use of zoledronic acid, a novel, highly potent bisphosphonate, for the treatment of hypercalcemia of malignancy. ( Major, P, 2002) |
| " They now constitute the standard treatment for cancer hypercalcemia, for which we recommend a dose of 1,500 mg of clodronate or 90 mg of pamidronate; the latter compound is more potent and has a longer lasting effect." | 4.80 | Current use of bisphosphonates in oncology. International Bone and Cancer Study Group. ( Bartl, R; Body, JJ; Burckhardt, P; Delmas, PD; Diel, IJ; Fleisch, H; Kanis, JA; Kyle, RA; Mundy, GR; Paterson, AH; Rubens, RD, 1998) |
| " The parent compound, etidronate, was first used in multicentered trials for the treatment of primary osteoporosis and showed some success in increasing bone density and perhaps controlling fracture rates." | 4.79 | Bisphosphonate therapy. ( Licata, AA, 1997) |
| "Pamidronate use in a CCI population is associated with reduced mortality, lower hypoglycemia rates, improved albumin, and stable renal function." | 3.83 | INTRAVENOUS PAMIDRONATE IS ASSOCIATED WITH REDUCED MORTALITY IN PATIENTS WITH CHRONIC CRITICAL ILLNESS. ( Casey, MF; Godbold, JH; Mechanick, JI; Moshier, EL; Rho, L; Schulman, RC; Zaidi, M, 2016) |
| "To verify radiomorphometric indices and fractal dimension (FD) in dental panoramic radiographs (DPRs) of children with different types of osteogenesis imperfecta (OI) and also to verify the effect of pamidronate (PAM) treatment in such panoramic analyses." | 3.83 | Dental panoramic indices and fractal dimension measurements in osteogenesis imperfecta children under pamidronate treatment. ( Acevedo, AC; Apolinário, AC; Castro, LC; de Melo, NS; de Paula, AP; de Paula, LM; de Souza Figueiredo, PT; Guimarães, AT; Leite, AF; Sindeaux, R, 2016) |
| "Zoledronic acid and pamidronate are the two bisphosphonates approved in the United States to reduce multiple myeloma skeletal complications." | 3.81 | Comparative effectiveness on survival of zoledronic acid versus pamidronate in multiple myeloma. ( Carson, K; Colditz, G; Gage, B; Luo, S; Sanfilippo, KM; Tomasson, M; Vij, R; Weilbaecher, K, 2015) |
| "We studied markers of bone turnover over a 6-month period after a single dose of zoledronic acid in 29 patients with multiple myeloma in remission who previously received 8 to 12 doses of pamidronate or zoledronate (NCT00577642)." | 3.80 | Biomarkers of bone remodeling in multiple myeloma patients to tailor bisphosphonate therapy. ( Anderson, KC; Ghobrial, IM; Laubach, JP; Munshi, NC; Nemani, N; Patel, CG; Raje, NS; Richardson, PG; Santo, L; Schlossman, RL; Scullen, TA; Yee, AJ, 2014) |
| "Osteonecrosis of the jaw is an adverse outcome associated with bisphosphonate treatment." | 3.79 | Sarcoglycans and integrins in bisphosphonate treatment: immunohistochemical and scanning electron microscopy study. ( Catalfamo, L; Centofanti, A; Cutroneo, G; De Ponte, FS; Favaloro, A; Runci, M; Siniscalchi, EN, 2013) |
| "These results suggest that etidronate may 1) inhibit the entry of NBPs into cells related to inflammation and/or necrosis, 2) inhibit the binding of NBPs to bone hydroxyapatite, 3) at least partly eliminate (or substitute for) NBPs that have already accumulated within bones, and thus 4) if used as a substitution drug for NBPs, be effective at treating or preventing NBP-associated osteonecrosis of the jaw." | 3.76 | Inhibition of necrotic actions of nitrogen-containing bisphosphonates (NBPs) and their elimination from bone by etidronate (a non-NBP): a proposal for possible utilization of etidronate as a substitution drug for NBPs. ( Endo, Y; Funayama, H; Kawamura, H; Kumamoto, H; Kuroishi, T; Oizumi, T; Sasaki, K; Sugawara, S; Takahashi, H; Yamaguchi, K; Yamamoto, M; Yokoyama, M, 2010) |
| " In this study, we investigated the possible direct effect of three N-containing BPs (alendronate, pamidronate, and zoledronate) on the specific activity of bone ALP obtained from an extract of UMR106 rat osteosarcoma cells." | 3.73 | Bone-specific alkaline phosphatase activity is inhibited by bisphosphonates: role of divalent cations. ( Cortizo, AM; McCarthy, AD; Vaisman, DN, 2005) |
| "In a cross-sectional study, 24-h urinary excretion of pamidronate and the biochemical marker of bone resorption N-terminal telopeptide of type 1 collagen and serum alkaline phosphatase were measured in 40 patients with bone metastases from breast cancer at the beginning, after 3-6 months, and after 1 year of treatment with intravenous pamidronate 90 mg every 3-4 weeks." | 3.73 | Skeletal retention of bisphosphonate (pamidronate) and its relation to the rate of bone resorption in patients with breast cancer and bone metastases. ( Cremers, SC; den Hartigh, J; Gelderblom, H; Papapoulos, SE; Seynaeve, C; van der Rijt, CC; van Zuylen, L; Vermeij, P, 2005) |
| " Pamidronate, an inhibitor of bone resorption used primarily in the management of tumor-induced hypercalcemia and Paget's disease, is reported to cause conjunctivitis, anterior uveitis, and infrequently episcleritis and scleritis." | 3.72 | Posterior uveitis: an under-recognized adverse effect of pamidronate: 2 case reports. ( Claes, C; Haverbeke, G; Pertile, G; Zeyen, T, 2003) |
| "Intravenous pamidronate is widely used to treat children with moderate to severe osteogenesis imperfecta (OI)." | 3.72 | Delayed osteotomy but not fracture healing in pediatric osteogenesis imperfecta patients receiving pamidronate. ( Fassier, F; Glorieux, FH; Munns, CF; Rauch, F; Zeitlin, L, 2004) |
| "Cyclical pamidronate infusions increase bone mass in children suffering from osteogenesis imperfecta." | 3.71 | The effects of intravenous pamidronate on the bone tissue of children and adolescents with osteogenesis imperfecta. ( Glorieux, FH; Plotkin, H; Rauch, F; Travers, R, 2002) |
| " pamidronate in patients with osteoporosis." | 3.71 | A pharmacokinetic and pharmacodynamic model for intravenous bisphosphonate (pamidronate) in osteoporosis. ( Cremers, S; den, HJ; Hamdy, N; Papapoulos, S; Sparidans, R; Vermeij, P, 2002) |
| " Thirty-seven patients with newly diagnosed bone metastases from breast cancer, randomized to receive oral pamidronate or placebo tablets in addition to anticancer treatment within the context of a multicentre EORTC trial, who were both assessable for radiographic response in bone and had serum and urine samples collected for more than 1 month were studied." | 3.70 | Assessment of bone response to systemic therapy in an EORTC trial: preliminary experience with the use of collagen cross-link excretion. European Organization for Research and Treatment of Cancer. ( Bastit, P; Coleman, R; Ford, J; Lacombe, D; Leonard, R; Michel, J; Mignolet, F; Nortier, J; Rose, C; Tubiana-Hulin, M; Vinholes, J; Wildiers, J, 1999) |
| "Autopsy specimens of a bone metastasis from a woman with a primary squamous cell carcinoma of the tongue who developed multiple osteolytic lesions and hypercalcemia and was treated with pamidronate were studied histologically, histochemically, and ultrastructurally." | 3.69 | Effects of bisphosphonate (pamidronate) on bone resorption resulting from metastasis of a squamous cell carcinoma: report of an autopsy case and evaluation of bone resorbing activity in an experimental animal model. ( Hiraga, T; Nakajima, T; Ozawa, H; Takada, M, 1996) |
| " We compared several new markers of bone turnover in normocalcaemic patients with breast cancer-induced osteolysis before and after a single infusion of the bisphosphonate pamidronate." | 3.69 | Comparative evaluation of markers of bone resorption in patients with breast cancer-induced osteolysis before and after bisphosphonate therapy. ( Body, JJ; Delmas, PD; Dumon, JC; Gineyts, E, 1997) |
| "Three children with osteogenesis imperfecta, severe osteopenia, and repeated fractures were treated with cyclic infusions of aminohydroxypropylidene bisphosphonate (pamidronate) for a period ranging from 22 to 29 months." | 3.69 | Intravenous pamidronate treatment in osteogenesis imperfecta. ( Bembi, B; Bottega, M; Ceschel, S; Ciana, G; Martini, C; Parma, A; Zanatta, M, 1997) |
| " The urinary excretion of these compounds, expressed as a ratio to urinary creatinine, has been measured using ion-pair reversed phase high-performance liquid chromatography in 20 patients receiving oral pamidronate for bone metastases from breast cancer." | 3.68 | Preliminary results of the use of urinary excretion of pyridinium crosslinks for monitoring metastatic bone disease. ( Coleman, RE; Ford, J; Houston, S; James, I; Leonard, RC; Rodger, A; Rubens, RD, 1992) |
| "28 patients with progressing painful bone metastases (18 breast cancer, 9 myeloma and 1 low grade lymphoma) received pamidronate 60 mg by 24 h continuous infusion for at least 2 courses (range 2-12)." | 3.68 | Treatment of bone metastases from breast cancer and myeloma with pamidronate. ( Burckhardt, P; Cornu, P; Leyvraz, S; Perey, L; Thiébaud, D; Thiébaud, S; von Fliedner, V, 1991) |
| "All patients had osteopenia, diminished osteoid formation and bone volume on histomorphometry pre-therapy with high turnover bone disease (HTO) in TM and low-turnover disease (LTO) in TI." | 2.77 | Prospective study of histomorphometry, biochemical bone markers and bone densitometric response to pamidronate in β-thalassaemia presenting with osteopenia-osteoporosis syndrome. ( Bajoria, R; Byers, M; Chatterjee, R; Davis, BA; Porter, JB; Pringle, J; Shah, FT; Sooranna, D, 2012) |
| "Pamidronate did not increase the risk of serious adverse events." | 2.74 | Pamidronate in the prevention of bone loss after liver transplantation: a randomized controlled trial. ( Barrios, C; Casafont, F; Clemente, G; De la Mata, M; García-González, M; Guañabens, N; Monegal, A; Navasa, M; Serrano, T; Suárez, F; Suárez, MJ; Tome, S; Torne, S, 2009) |
| " Immunosuppression was cyclosporine and prednisolone, with no difference in dosing between the 2 groups." | 2.74 | Effect of pamidronate on bone loss after kidney transplantation: a randomized trial. ( Altmann, P; Andrews, C; Banks, LM; Cockwell, P; Cunningham, J; Dudley, C; Hall-Craggs, M; Noonan, K; Pattison, J; Sweny, P; Walsh, SB; Wilkie, M; Yaqoob, MM, 2009) |
| "Osteoporosis is a long-term complication of allogeneic stem cell transplantation (SCT)." | 2.72 | Serum osteoprotegerin and receptor activator of nuclear factor-kappaB ligand (RANKL) concentrations in allogeneic stem cell transplant-recipients: a role in bone loss? ( Kananen, K; Laitinen, K; Ruutu, T; Välimäki, MJ; Volin, L, 2006) |
| "Osteoprotegerin (OPG) is a decoy receptor for OPG ligand (OPGL), or receptor activator of NF-kappaB ligand (RANKL)." | 2.71 | A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. ( Bekker, PJ; Body, JJ; Coleman, RE; Dunstan, CR; Facon, T; Fermand, JP; Geurs, F; Greipp, P; Harousseau, JL; Holloway, D; Lipton, A; Mariette, X; Martin, SW; Nakanishi, A; Williams, CD, 2003) |
| "Pamidronate treatment suppresses excretion of total DPD." | 2.71 | Effect of pamidronate on excretion of pyridinium crosslinks of collagen after total hip arthroplasty. ( Eastell, R; Jackson, B; Wilkinson, JM, 2003) |
| "Rate of bone resorption was assessed by the biochemical markers: serum carboxy terminal cross-linked telopeptide of type I collagen, urinary carboxy terminal cross-linked telopeptide of type I collagen normalized to creatinine and urinary amino-terminal telopeptide of type I collagen normalized to creatinine; and rate of cartilage degradation by urinary carboxy terminal telopeptide of type II collagen normalized to creatinine." | 2.71 | Short term whole body retention in relation to rate of bone resorption and cartilage degradation after intravenous bisphosphonate (pamidronate) in rheumatoid arthritis. ( Cremers, SC; Den Hartigh, J; Dijkmans, BA; Lems, WF; Lodder, MC; Papapoulos, SE; Van Pelt, P; Vermeij, P, 2004) |
| "Pamidronate (60 mg) was administered intravenously 14 days before bed rest." | 2.71 | Intravenous pamidronate prevents femoral bone loss and renal stone formation during 90-day bed rest. ( Felsenberg, D; Fukunaga, M; Kohri, K; Matsumoto, T; Mizuno, K; Nakamura, T; Ohshima, H; Rittweger, J; Sekiguchi, C; Watanabe, Y, 2004) |
| "Pamidronate therapy was associated with suppression of all biochemical markers of bone turnover compared with placebo (repeated measures ANOVA; p < 0." | 2.70 | Effect of pamidronate in preventing local bone loss after total hip arthroplasty: a randomized, double-blind, controlled trial. ( Barrington, NA; Eastell, R; Elson, RA; Hamer, AJ; Peel, NF; Stockley, I; Wilkinson, JM, 2001) |
| "This study evaluated the dose-response relation for zoledronic acid, a new generation high potency bisphosphonate, given as a 5-minute infusion in patients with malignant osteolytic disease." | 2.70 | Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases. ( Berenson, JR; Coleman, RE; Dreicer, R; Howell, A; Kuross, SA; Lipton, A; Morley, W; Porter, L; Rosen, LS; Seaman, JJ, 2001) |
| "Skeletal metastases from thyroid cancer are poorly responsive to medical or radioiodine treatment." | 2.70 | Pamidronate improves the quality of life and induces clinical remission of bone metastases in patients with thyroid cancer. ( Abbruzzese, A; Caraglia, M; Ciccarelli, A; Fonderico, F; Lupoli, G; Martignetti, A; Nuzzo, V; Vitale, G, 2001) |
| "Bone resorption was assessed by measurement of urinary collagen crosslinks." | 2.70 | Comparison of the effects of intravenous pamidronate and oral clodronate on symptoms and bone resorption in patients with metastatic bone disease. ( Coleman, RE; Heatley, S; Herling, C; Jagdev, SP; Purohit, P, 2001) |
| "Osteoporosis is a common and serious complication of solid organ transplantation." | 2.70 | Effects of a single infusion of pamidronate prior to liver transplantation: a bone histomorphometric study. ( Alexander, GJ; Compston, JE; Garrahan, NJ; Ninkovic, M; Vedi, S, 2002) |
| "We found that urinary markers of bone resorption are best measured on 2-hour fasting samples, because results on random urine showed poor precision and less decline with therapy." | 2.69 | Utility of biochemical markers of bone turnover in the follow-up of patients treated with bisphosphonates. ( Garber, J; Greenspan, SL; Lee, SL; Moses, AC; Rosen, HN; Ross, DS, 1998) |
| "Pamidronate was administered at a monthly dose of 90 mg iv, and the above parameters were evaluated at the beginning of this study and after 1, 3, 6, 9, 12 and 14 months of treatment." | 2.69 | Effect of pamidronate administration on markers of bone turnover and disease activity in multiple myeloma. ( Anargyrou, K; Meletis, J; Palermos, J; Papassavas, P; Terpos, E; Tsionos, K; Viniou, N; Yataganas, X, 2000) |
| "We have evaluated the value of specific bone resorption markers in monitoring metastatic bone disease to define the duration of action of a single high-dose pamidronate infusion." | 2.68 | Metabolic effects of pamidronate in patients with metastatic bone disease. ( Coleman, RE; Eastell, R; Guo, CY; Purohit, OP; Vinholes, J, 1996) |
| " In a randomized phase III trial of 377 patients with multiple myeloma, Aredia was administered in a dosage of 90 mg i." | 2.68 | The role of bisphosphonates in the treatment of bone metastases--the U.S. experience. ( Harvey, HA; Lipton, A, 1996) |
| "Pamidronate treatment for Paget's disease of bone leads to a sustained inhibition of elevated bone turnover." | 2.68 | [Bisphosphonate therapy of Paget's disease of bone with pamidronate]. ( Grauer, A; Klar, B; Knaus, J; Scharla, SH; Ziegler, R, 1996) |
| "Urinary parameters of bone resorption, free pyridinolines (Pyr) and hydroxyproline (OHP), as well as serum tartrate-resistant acid phosphatase (TRAP) were measured." | 2.68 | Pamidronate and biochemical markers of bone turnover. ( Del Campo, MT; Gijón, J; Martínez, ME; Plaza, MA; Torrijos, A, 1997) |
| "The new bone resorption markers of collagen breakdown were able to predict clinical response to pamidronate." | 2.68 | Relationships between biochemical and symptomatic response in a double-blind randomised trial of pamidronate for metastatic bone disease. ( Abbey, ME; Coleman, RE; Eastell, R; Purohit, OP; Vinholes, JJ, 1997) |
| "Thirty-three cancer patients remaining hypercalcemic after a 48-h rehydration period were included and monitored daily until normocalcemia or treatment failure was documented." | 2.66 | Aminohydroxypropylidene bisphosphonate (APD) treatment for tumor-associated hypercalcemia: a randomized comparison between a 3-day treatment and single 24-hour infusions. ( Body, JJ; Borkowski, A; Magritte, A; Sculier, JP; Seraj, F, 1989) |
| "Hypercalcemia is sustained by an inability of the kidney to deal efficiently with a chronically increased calcium load." | 2.66 | Role of bone and kidney in tumor-induced hypercalcemia and its treatment with bisphosphonate and sodium chloride. ( Bijvoet, OL; Body, JJ; Elte, JW; Harinck, HI; Neijt, JP; Plantingh, AS; Sleeboom, HP; Wildiers, J, 1987) |
| "As hypercalcemia is a serious metabolic complication, a gradual dose reduction should be considered when interruption of high dose denosumab therapy is planned." | 2.61 | Acute hypercalcemia and excessive bone resorption following anti-RANKL withdrawal: Case report and brief literature review. ( Brazeau-Lamontagne, L; Dufresne, J; Huot Daneault, A; Massicotte, MH; Roux, S, 2019) |
| "Inhibitors of bone resorption have been used to suppress bone turnover in the short term, but there is no published data on long-term efficacy." | 2.42 | Treatment of idiopathic hyperphosphatasia with intensive bisphosphonate therapy. ( Cundy, T; King, A; Wheadon, L, 2004) |
| "The major clinical manifestations of multiple myeloma are related to the loss of bone." | 2.41 | Advances in the biology and treatment of myeloma bone disease. ( Berenson, JR, 2002) |
| "Hypercalcemia of malignancy (HCM) is a potentially life-threatening complication of cancer resulting from increased bone resorption by osteoclasts." | 2.41 | Treatment of hypercalcemia of malignancy with bisphosphonates. ( Berenson, JR, 2002) |
| "Oral etidronate has been found to be ineffective in patients with multiple myeloma and prostate carcinoma bone metastases." | 2.41 | Oral bisphosphonates: A review of clinical use in patients with bone metastases. ( Berenson, J; Hortobagyi, G; Lipton, A; Major, PP, 2000) |
| "Many of the bisphosphonates inhibit bone resorption, the newest compounds being 10,000 times more active than etidronate, the first bisphosphonate described." | 2.40 | Bisphosphonates: preclinical aspects and use in osteoporosis. ( Fleisch, HA, 1997) |
| "Pamidronate is a second-generation aminobisphosphonate that is a much more potent inhibitor of osteoclastic activity." | 2.40 | Bisphosphonates and breast carcinoma. ( Lipton, A, 1997) |
| "Pamidronate (APD) is a potent inhibitor of bone resorption that is useful in the management of patients with osteolytic bone metastases from breast cancer or multiple myeloma, tumour-induced hypercalcaemia or Paget's disease of bone." | 2.40 | Pamidronate. A review of its use in the management of osteolytic bone metastases, tumour-induced hypercalcaemia and Paget's disease of bone. ( Coukell, AJ; Markham, A, 1998) |
| " Long term use of low-dose pamidronate in conjunction with conventional antiosteoporotic therapy may halt bone loss in steroid-induced and idiopathic osteoporosis." | 2.38 | Pamidronate. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease. ( Fitton, A; McTavish, D, 1991) |
| "Fast bone resorption and formation lead to the development of disorganized bone tissue." | 1.72 | Updates on Paget's Disease of Bone. ( Choi, YJ; Chung, YS; Sohn, YB, 2022) |
| "Pamidronate treatment of G11-Tg mice restored the trabecular bone loss phenotype, as bone mineral density, bone volume, trabecular number, separation, and expressions of osteoblastic and osteoclastic genes were comparable with WT parameters." | 1.43 | Elevated Gα11 expression in osteoblast lineage cells promotes osteoclastogenesis and leads to enhanced trabecular bone accrual in response to pamidronate. ( Dela Cruz, A; Grynpas, MD; Mitchell, J, 2016) |
| "Pamidronate treatment protected mice from cortical bone loss but did not increase bone strength." | 1.43 | Prophylactic pamidronate partially protects from glucocorticoid-induced bone loss in the mdx mouse model of Duchenne muscular dystrophy. ( Chen, J; Grynpas, MD; Mitchell, J; Yoon, SH, 2016) |
| "Treatment with alendronate, pamidronate, and zoledronate, but not clodronate, led to a decrease in the number of chondrocytes per column in the hypertrophic chondrocyte layer." | 1.40 | Effect of bisphosphonates on the rapidly growing male murine skeleton. ( Bouxsein, ML; Brooks, DJ; Demay, MB; Louis, L; Zhu, ED, 2014) |
| "The level of bone resorption might impact cartilage remodeling." | 1.38 | Targeting bone alleviates osteoarthritis in osteopenic mice and modulates cartilage catabolism. ( Ah Kioon, MD; Cohen-Solal, ME; de Vernejoul, MC; Funck-Brentano, T; Hannouche, D; Hay, E; Lin, H; Lioté, F; Nizard, R; Orcel, P; Schiltz, C, 2012) |
| "Pamidronate was then administered sc (0." | 1.37 | Calcitropic hormones and IGF-I are influenced by dietary protein. ( Ammann, P; Brennan, TC; Dayer, R; Dubois-Ferrière, V; Rizzoli, R, 2011) |
| "Targeting bone resorption might therefore provide an approach to the treatment of high bone resorbing forms of OA." | 1.36 | Inhibition of bone resorption blunts osteoarthritis in mice with high bone remodelling. ( Cohen-Solal, ME; Ea, HK; Funck-Brentano, T; Geoffroy, V; Hannouche, D; Kadri, A; Lin, H; Lioté, F; Marty, C, 2010) |
| "osteoprotegerin (OPG) in inhibiting bone resorption and tooth movement, using a new orthodontic model in mice in which maxillary molars are moved for prolonged periods by near-constant, clinically relevant forces." | 1.34 | Inhibition of tooth movement by osteoprotegerin vs. pamidronate under conditions of constant orthodontic force. ( Darendeliler, MA; Difuria, C; Gagari, E; Grunes, B; Keles, A; Kent, R; Muller, R; Srinivasan, V; Stashenko, P, 2007) |
| "Hypercalcemia was induced either by sc inoculation of syngeneic colon (C-26) adenocarcinoma cells or by sc injection of high-dose recombinant PTHrP (0." | 1.33 | The inhibition of RANKL causes greater suppression of bone resorption and hypercalcemia compared with bisphosphonates in two models of humoral hypercalcemia of malignancy. ( Adamu, S; Asuncion, F; Capparelli, C; Dunstan, CR; Geng, Z; Grisanti, M; Kostenuik, PJ; Morony, S; Starnes, C; Tan, HL; Warmington, K; Weimann, B, 2005) |
| "Pamidronate treatment of the patient also reduced the number of synovial fluid macrophages and resulted in less osteoclast formation and lacunar resorption." | 1.33 | Osteoclast differentiation and bone resorption in multicentric reticulohistiocytosis. ( Adamopoulos, IE; Athanasou, NA; Edwards, JR; Ferguson, DJ; Wordsworth, PB, 2006) |
| "Conversely, in Paget's disease and prostate cancer-induced bone metastases, conditions characterized by focal increased bone turnover, alpha L CTX levels were more elevated than those of age-related CTX forms, resulting in increased ratios between native and age-modified CTX." | 1.32 | Investigation of bone disease using isomerized and racemized fragments of type I collagen. ( Body, JJ; Christgau, S; Christiansen, C; Cloos, PA; Delmas, P; Engsig, M; Fledelius, C; Garnero, P, 2003) |
| "By inhibiting bone resorption, bisphosphonate administration caused transient normalization of calcemia, associated with improved FIM, at a significantly higher level than in untreated patients (+16." | 1.32 | A single bisphosphonate infusion is associated with improved functional capacity in elderly subjects with primary hyperparathyroidism. ( Ammann, P; Herter-Clavel, C; Lubrano, A; Rizzoli, R, 2003) |
| "Neovascularisation and bone resorption are related to myeloma disease activity." | 1.32 | Serum syndecan-1, basic fibroblast growth factor and osteoprotegerin in myeloma patients at diagnosis and during the course of the disease. ( Angelopoulou, MK; Dimopoulou, MN; Gribabis, DA; Kokoris, SI; Kyrtsonis, MC; Pangalis, GA; Siakantaris, MP; Vassilakopoulos, TP, 2004) |
| "Zoledronic acid (6i) has thus been selected for clinical development under the registered trade name Zometa." | 1.31 | Highly potent geminal bisphosphonates. From pamidronate disodium (Aredia) to zoledronic acid (Zometa). ( Bachmann, R; Bisping, M; Born, AR; Cortesi, R; Glatt, M; Green, JR; Guiglia, G; Jaeggi, KA; Jeker, H; Klein, R; Müller, K; Ramseier, U; Schmid, J; Schreiber, G; Seltenmeyer, Y; Widler, L, 2002) |
| "Hypercalcemia is a serious complication of malignancies, but it is uncommon in acute leukemia." | 1.31 | Megakaryoblastic transformation of polycythemia vera with hypercalcemia. ( Iwasaki, H; Kurosawa, M, 2002) |
| "A strategy that blocks localized bone resorption may prevent the progression of the disease." | 1.31 | Inhibition of cholesteatomatous bone resorption with pamidronate disodium. ( Chung, JW; Kim, HJ; Lee, SH; Park, MH; Yoon, TH, 2001) |
| "Pamidronate treatment increased secondary cancellous bone but could not restore normal growth-induced periosteal bone apposition and bone strength." | 1.30 | Inhibition of bone resorption by pamidronate cannot restore normal gain in cortical bone mass and strength in tail-suspended rapidly growing rats. ( Fukumoto, S; Fuse, H; Kawahara, H; Kodama, Y; Kurokawa, T; Matsumoto, T; Nakamura, T; Nakayama, K; Sekiguchi, C; Takahashi, H, 1997) |
| "Pamidronate does not inhibit the gene expression of the putative tooth eruption molecules, colony-stimulating factor-1 and c-fos, both of which are expressed in the dental follicle, the tissue that is required for eruption to occur." | 1.30 | Inhibition of tooth eruption in the rat by a bisphosphonate. ( Grier, RL; Wise, GE, 1998) |
| "The total number of new bone fractures and total number of patients with new fractures were less frequent during the pamidronate treatment period than before (p < 0." | 1.30 | [Extended use, up to 6 years, of an oral amino-bisphosphonate in patients with established osteoporosis]. ( Bogado, C; Plotkin, H; Roldán, EJ; Sarli, M; Spivacow, RF; Zanchetta, JR, 1997) |
| "PTHrP stimulates osteoclastic bone resorption and renal calcium reabsorption through the activation of a receptor similar to that of PTH (PTH-R)." | 1.30 | Pamidronate corrects the down-regulation of the renal parathyroid hormone (PTH)/PTH-related peptide (PTHrP) receptor mRNA in rats bearing Walker tumors. ( Bouizar, Z; de Vernejoul, MC; Denne, MA; Morieux, C; Ureña, P; Yaghoobian, J, 1998) |
| "This increased bone resorption is inhibited by pamidronate without reducing G-CSF-induced HPC mobilization, suggesting that the activation of bone resorption after G-CSF administration is not the direct cause of HPC mobilization as initially hypothesized, but a parallel event." | 1.30 | Osteoclast-mediated bone resorption is stimulated during short-term administration of granulocyte colony-stimulating factor but is not responsible for hematopoietic progenitor cell mobilization. ( Lévesque, JP; Moore, RJ; Morris, HA; Simmons, PJ; Takamatsu, Y; To, LB, 1998) |
| "With respect to markers of bone resorption, urinary deoxypyridinoline fell by 51% +/- 9% in group A patients and increased by 65% +/- 22% in group B patients by 3 months after transplantation (P < ." | 1.30 | Prevention of bone loss after heart transplantation with antiresorptive therapy: a pilot study. ( Addesso, V; Lo, SH; Mancini, D; McMahon, DJ; Michler, RE; Rodino, MA; Seibel, MJ; Shane, E; Staron, RB, 1998) |
| "The baseline levels of bone resorption markers were used to predict the probability of non-progressive bone disease or reduction in pain intensity during bisphosphonate therapy." | 1.30 | Diagnostic and prognostic value of biochemical markers in malignant bone disease: a prospective study on the effect of bisphosphonate on pain intensity and progression of malignant bone disease. ( Engler, H; Koeberle, D; Riesen, WF; Senn, HJ; Thuerlimann, B, 1998) |
| "The accelerated osteoclastic bone resorption induced by rhG-CSF was suppressed by the pharmacological activity of AHPrBP." | 1.30 | The development of bone changes induced in rats by recombinant human granulocyte colony-stimulating factor is suppressed by bisphosphonate. ( Adachi, K; Doi, K; Nakayama, H; Sugimoto, T; Suzuki, M, 1999) |
| "MMP-2 is involved both in bone resorption and in the metastatic process." | 1.30 | Zoledronate is a potent inhibitor of myeloma cell growth and secretion of IL-6 and MMP-1 by the tumoral environment. ( Amiot, M; Barillé, S; Bataille, R; Berthaud, P; Collette, M; Derenne, S; Harousseau, JL; Robillard, N, 1999) |
| "Pamidronate therapy was effective in restoring serum calcium to normal." | 1.29 | Hypercalcaemia in primary oxalosis: role of increased bone resorption and effects of treatment with pamidronate. ( Barnes, ND; Compston, JE; Grant, J; Jamieson, N; Noble-Jamieson, G; Yamaguchi, K, 1995) |
| "Alendronate is an aminobisphosphonate that acts as a potent inhibitor of osteoclastic bone resorption." | 1.29 | Alendronate distributed on bone surfaces inhibits osteoclastic bone resorption in vitro and in experimental hypercalcemia models. ( Azuma, Y; Kiyoki, M; Ohta, T; Okabe, K; Oue, Y; Sato, H; Tsuchimoto, M, 1995) |
| "To test the role of bone resorption in the response of the bone to mechanical stimulation, we compared the anabolic response to a single period of loading, of rats treated with 3-amino-1-hydroxypropylidene-1-bisphosphonate (AHPrBP) or vehicle." | 1.29 | Stimulation of bone formation by dynamic mechanical loading of rat caudal vertebrae is not suppressed by 3-amino-1-hydroxypropylidene-1-bisphosphonate (AHPrBP). ( Chambers, TJ; Chow, JW; Jagger, CJ, 1995) |
| "The goal of this study was to find out if bone can recover after long-term administration of bisphosphonate." | 1.29 | Recovery from pamidronate (APD): a two-year study in the dog. ( Dumitriu, M; Grynpas, MD; Kasra, M; Mertz, BP; Nespeca, R; Very, JM, 1994) |
| "In all 24 patients studied, bone resorption (measured by urinary hydroxyproline/creatinine ratio, OHP/Cr) fell sharply on treatment, from 0." | 1.29 | Long-term elevation of 1,25-dihydroxyvitamin D after short-term intravenous administration of pamidronate (aminohydroxypropylidene bisphosphonate, APD) in Paget's disease of bone. ( Devlin, RD; Fenton, AJ; Grill, V; Gutteridge, DH; Kent, GN; Prince, RL; Retallack, RW; Worth, GK, 1994) |
| "The rate and degree of suppression of bone resorption were monitored in 6 of the patients similarly treated with intravenous dimethyl-APD at a dose of 4 mg/day for 10 days, by daily measurements of the 24 h urinary excretion of Pyr, Dpyr and OHP." | 1.29 | Urinary collagen crosslink excretion: a better index of bone resorption than hydroxyproline in Paget's disease of bone? ( Colwell, A; Eastell, R; Hamdy, NA; Papapoulos, SE; Russell, RG, 1993) |
| "Pamidronate (APD) is a bisphosphonate that prevents bone loss from a variety of causes." | 1.29 | Parenteral pamidronate prevents thyroid hormone-induced bone loss in rats. ( Dresner-Pollak, R; Greenspan, SL; Gundberg, C; Hock, JM; Maitland, LA; Middlebrooks, VL; Moses, AC; Rosen, HN; Sullivan, EK; Zeind, AJ, 1993) |
| "Primary hyperparathyroidism is usually associated with normal or elevated serum 1,25-dihydroxyvitamin D [1,25(OH)2D] levels." | 1.29 | Inhibition of 1,25(OH)2D production by hypercalcemia in osteitis fibrosa cystica: influence on parathyroid hormone secretion and hungry bone disease. ( Brossard, JH; D'Amour, P; Garon, J; Gascon-Barré, M; Lepage, R, 1993) |
| "Pamidronate treatment resulted in a brisk reduction in plasma calcium concentration." | 1.29 | Vitamin D intoxication causes hypercalcaemia by increased bone resorption which responds to pamidronate. ( Davies, M; Marks, JS; Mawer, EB; Selby, PL, 1995) |
| "Pamidronate was the only agent tested which suppressed the increase in bone resorption associated with macrophage exposure to bone cement particles to levels which were not significantly different from unexposed calvaria." | 1.29 | Pharmacologic inhibition of particulate-induced bone resorption. ( Algan, SA; Horowitz, SM; Purdon, MA, 1996) |
| " In osteoporotic syndromes, APD is prescribed at a lower dosage (200 mg/day) and currently calcium or vitamin D are also systematically added." | 1.29 | [Effect of low doses of oral pamidronate (APD) on the calcemia of osteopenic or osteoporotic patients]. ( Castelli, G; Kerzberg, EM; Lloret, AP; Roldan, EJ, 1996) |
| " The experimental conditions provide a technically simple method which is sensitive enough to examine antiresorptive properties in a healthy animal and to detect adverse effects on the kidney." | 1.28 | Measurement of serum [3H]tetracycline kinetics and indices of kidney function facilitate study of the activity and toxic effects of bisphosphonates in bone resorption. ( Eitan, Y; Golomb, G; Hoffman, A, 1992) |
| "Thus, the increased bone resorption, which is a consequence of estrogen-deficiency, entrains increased bone formation, which masks a simultaneous reduction in estrogen-dependent bone formation." | 1.28 | Estrogen maintains trabecular bone volume in rats not only by suppression of bone resorption but also by stimulation of bone formation. ( Chambers, TJ; Chow, J; Colston, KW; Tobias, JH, 1992) |
| "Treatment with pamidronate resulted in a higher BMC of the lumbar spine than in the untreated animals, with elevated concentrations of hPTH." | 1.28 | Pamidronate reduces PTH-mediated bone loss in a gene transfer model of hyperparathyroidism in rats. ( Dobrolet, NC; Mitlak, BH; Neer, RM; Nussbaum, SR; Rodda, CP; Von Deck, MD, 1991) |
| "It inhibited arotinoid-stimulated bone resorption as assessed by calcemia in thyroparathyroidectomized rats at a SC dose as low as 0." | 1.28 | BM 21.0955, a potent new bisphosphonate to inhibit bone resorption. ( Bauss, F; Bosies, E; Fleisch, H; Janner, M; Mühlbauer, RC; Schenk, R; Strein, K, 1991) |
| "Bone resorption was virtually abolished on bone slices preincubated in 10(-3) M AHPrBP." | 1.28 | Inhibition of bone resorption by bisphosphonates: interactions between bisphosphonates, osteoclasts, and bone. ( Chambers, TJ; Flanagan, AM, 1991) |
| "Significant inhibition of bone resorption in each case is seen only after 24-72 h of treatment." | 1.28 | Bisphosphonates directly inhibit the bone resorption activity of isolated avian osteoclasts in vitro. ( Blair, HC; Carano, A; Konsek, JD; Schlesinger, PH; Teitelbaum, SL, 1990) |
| "Eight patients with cancer associated hypercalcaemia were treated with the combination of aminohydroxypropylidene diphosphonate and salmon calcitonin for six days." | 1.27 | Treatment of cancer associated hypercalcaemia with combined aminohydroxypropylidene diphosphonate and calcitonin. ( Alzaid, AA; Boyle, IT; Gardner, MD; Ralston, SH, 1986) |
| "In order to inhibit bone resorption, 35-day-old mice were given 16 mumol/kg/day of (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate (AHPrBP) for 10 days, the first injection occurring 3 days prior to the continuous infusion of 0." | 1.27 | Inhibition by aminohydroxypropylidene bisphosphonate (AHPrBP) of 1,25(OH)2 vitamin D3-induced stimulated bone turnover in the mouse. ( Garba, MT; Hott, M; Marie, PJ, 1985) |
| " Serum calcium and 1,25-dihydroxyvitamin D levels remained normal at all dosage levels." | 1.27 | Inhibition of bone matrix apposition by (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (AHPrBP) in the mouse. ( Garba, MT; Hott, M; Marie, PJ, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 27 (11.54) | 18.7374 |
| 1990's | 106 (45.30) | 18.2507 |
| 2000's | 78 (33.33) | 29.6817 |
| 2010's | 19 (8.12) | 24.3611 |
| 2020's | 4 (1.71) | 2.80 |
| Authors | Studies |
|---|---|
| Szajnman, SH | 1 |
| Bailey, BN | 1 |
| Docampo, R | 1 |
| Rodriguez, JB | 1 |
| Szabo, CM | 2 |
| Matsumura, Y | 1 |
| Fukura, S | 1 |
| Martin, MB | 2 |
| Sanders, JM | 2 |
| Sengupta, S | 1 |
| Cieslak, JA | 1 |
| Loftus, TC | 1 |
| Lea, CR | 1 |
| Lee, HJ | 1 |
| Koohang, A | 1 |
| Coates, RM | 1 |
| Sagami, H | 1 |
| Oldfield, E | 4 |
| Widler, L | 1 |
| Jaeggi, KA | 1 |
| Glatt, M | 1 |
| Müller, K | 1 |
| Bachmann, R | 1 |
| Bisping, M | 1 |
| Born, AR | 1 |
| Cortesi, R | 1 |
| Guiglia, G | 1 |
| Jeker, H | 1 |
| Klein, R | 1 |
| Ramseier, U | 1 |
| Schmid, J | 1 |
| Schreiber, G | 1 |
| Seltenmeyer, Y | 1 |
| Green, JR | 1 |
| Song, Y | 1 |
| Chan, JM | 1 |
| Zhang, Y | 1 |
| Jennings, S | 1 |
| Kosztowski, T | 1 |
| Odeh, S | 1 |
| Flessner, R | 1 |
| Schwerdtfeger, C | 1 |
| Kotsikorou, E | 2 |
| Meints, GA | 1 |
| Gómez, AO | 1 |
| González-Pacanowska, D | 1 |
| Raker, AM | 1 |
| Wang, H | 1 |
| van Beek, ER | 1 |
| Papapoulos, SE | 13 |
| Morita, CT | 1 |
| Abdou, WM | 1 |
| Ganoub, NA | 1 |
| Geronikaki, A | 1 |
| Sabry, E | 1 |
| Nakamura, M | 1 |
| Ueda, K | 1 |
| Yamamoto, Y | 1 |
| Aoki, K | 1 |
| Zhang, M | 1 |
| Saito, N | 1 |
| Yudasaka, M | 1 |
| Choi, YJ | 1 |
| Sohn, YB | 1 |
| Chung, YS | 1 |
| Klein, GL | 2 |
| Spirlandeli, AL | 1 |
| Dick-de-Paula, I | 1 |
| Zamarioli, A | 1 |
| Jorgetti, V | 1 |
| Ramalho, LNZ | 1 |
| Nogueira-Barbosa, MH | 1 |
| Volpon, JB | 1 |
| Jordão, AA | 1 |
| Cunha, FQ | 1 |
| Fukada, SY | 1 |
| de Paula, FJA | 1 |
| Cha, JK | 1 |
| Sun, YK | 1 |
| Kim, MJ | 1 |
| Sanz, M | 1 |
| Jung, UW | 1 |
| Roux, S | 1 |
| Massicotte, MH | 1 |
| Huot Daneault, A | 1 |
| Brazeau-Lamontagne, L | 1 |
| Dufresne, J | 1 |
| De Ponte, FS | 1 |
| Favaloro, A | 1 |
| Siniscalchi, EN | 1 |
| Centofanti, A | 1 |
| Runci, M | 1 |
| Cutroneo, G | 1 |
| Catalfamo, L | 1 |
| Zhu, ED | 1 |
| Louis, L | 1 |
| Brooks, DJ | 1 |
| Bouxsein, ML | 1 |
| Demay, MB | 1 |
| Sanfilippo, KM | 1 |
| Gage, B | 1 |
| Luo, S | 1 |
| Weilbaecher, K | 1 |
| Tomasson, M | 1 |
| Vij, R | 1 |
| Colditz, G | 1 |
| Carson, K | 1 |
| Patel, CG | 1 |
| Yee, AJ | 1 |
| Scullen, TA | 1 |
| Nemani, N | 1 |
| Santo, L | 1 |
| Richardson, PG | 1 |
| Laubach, JP | 1 |
| Ghobrial, IM | 1 |
| Schlossman, RL | 1 |
| Munshi, NC | 1 |
| Anderson, KC | 1 |
| Raje, NS | 1 |
| Criscitiello, C | 1 |
| Viale, G | 1 |
| Gelao, L | 1 |
| Esposito, A | 1 |
| De Laurentiis, M | 1 |
| De Placido, S | 1 |
| Santangelo, M | 1 |
| Goldhirsch, A | 1 |
| Curigliano, G | 1 |
| Schulman, RC | 1 |
| Moshier, EL | 1 |
| Rho, L | 1 |
| Casey, MF | 1 |
| Godbold, JH | 1 |
| Zaidi, M | 1 |
| Mechanick, JI | 2 |
| Apolinário, AC | 1 |
| Sindeaux, R | 1 |
| de Souza Figueiredo, PT | 1 |
| Guimarães, AT | 1 |
| Acevedo, AC | 1 |
| Castro, LC | 1 |
| de Paula, AP | 1 |
| de Paula, LM | 1 |
| de Melo, NS | 1 |
| Leite, AF | 1 |
| Dela Cruz, A | 1 |
| Grynpas, MD | 4 |
| Mitchell, J | 2 |
| Yoon, SH | 1 |
| Chen, J | 1 |
| Monegal, A | 1 |
| Guañabens, N | 1 |
| Suárez, MJ | 1 |
| Suárez, F | 1 |
| Clemente, G | 1 |
| García-González, M | 1 |
| De la Mata, M | 1 |
| Serrano, T | 1 |
| Casafont, F | 1 |
| Tome, S | 1 |
| Torne, S | 1 |
| Barrios, C | 1 |
| Navasa, M | 1 |
| Lomashvili, KA | 1 |
| Monier-Faugere, MC | 1 |
| Wang, X | 1 |
| Malluche, HH | 1 |
| O'Neill, WC | 1 |
| Walsh, SB | 1 |
| Altmann, P | 1 |
| Pattison, J | 1 |
| Wilkie, M | 1 |
| Yaqoob, MM | 1 |
| Dudley, C | 1 |
| Cockwell, P | 1 |
| Sweny, P | 1 |
| Banks, LM | 1 |
| Hall-Craggs, M | 1 |
| Noonan, K | 1 |
| Andrews, C | 1 |
| Cunningham, J | 1 |
| Oizumi, T | 1 |
| Funayama, H | 1 |
| Yamaguchi, K | 2 |
| Yokoyama, M | 1 |
| Takahashi, H | 2 |
| Yamamoto, M | 1 |
| Kuroishi, T | 1 |
| Kumamoto, H | 1 |
| Sasaki, K | 1 |
| Kawamura, H | 1 |
| Sugawara, S | 1 |
| Endo, Y | 1 |
| Kadri, A | 1 |
| Funck-Brentano, T | 2 |
| Lin, H | 2 |
| Ea, HK | 1 |
| Hannouche, D | 2 |
| Marty, C | 1 |
| Lioté, F | 2 |
| Geoffroy, V | 1 |
| Cohen-Solal, ME | 2 |
| Heras, P | 1 |
| Hatzopoulos, A | 1 |
| Heras, V | 1 |
| Kritikos, N | 1 |
| Karagiannis, S | 1 |
| Kritikos, K | 1 |
| Hussein, O | 1 |
| Tiedemann, K | 1 |
| Komarova, SV | 1 |
| Dubois-Ferrière, V | 1 |
| Brennan, TC | 1 |
| Dayer, R | 1 |
| Rizzoli, R | 4 |
| Ammann, P | 2 |
| Hay, E | 1 |
| Ah Kioon, MD | 1 |
| Schiltz, C | 1 |
| Nizard, R | 1 |
| Orcel, P | 1 |
| de Vernejoul, MC | 4 |
| Chatterjee, R | 1 |
| Shah, FT | 1 |
| Davis, BA | 1 |
| Byers, M | 1 |
| Sooranna, D | 1 |
| Bajoria, R | 1 |
| Pringle, J | 1 |
| Porter, JB | 1 |
| Isaia, GC | 1 |
| Lala, R | 1 |
| Defilippi, C | 1 |
| Matarazzo, P | 1 |
| Andreo, M | 1 |
| Roggia, C | 1 |
| Priolo, G | 1 |
| de Sanctis, C | 1 |
| Fernández, D | 1 |
| Vega, D | 1 |
| Goeta, A | 1 |
| Cloos, PA | 1 |
| Fledelius, C | 2 |
| Christgau, S | 1 |
| Christiansen, C | 2 |
| Engsig, M | 1 |
| Delmas, P | 1 |
| Body, JJ | 10 |
| Garnero, P | 2 |
| Rauch, F | 3 |
| Travers, R | 2 |
| Plotkin, H | 3 |
| Glorieux, FH | 5 |
| Kurosawa, M | 1 |
| Iwasaki, H | 1 |
| Major, P | 1 |
| Berenson, JR | 4 |
| Greipp, P | 1 |
| Coleman, RE | 10 |
| Facon, T | 1 |
| Geurs, F | 1 |
| Fermand, JP | 1 |
| Harousseau, JL | 2 |
| Lipton, A | 9 |
| Mariette, X | 1 |
| Williams, CD | 1 |
| Nakanishi, A | 1 |
| Holloway, D | 1 |
| Martin, SW | 1 |
| Dunstan, CR | 2 |
| Bekker, PJ | 1 |
| Gutteridge, DH | 2 |
| Retallack, RW | 2 |
| Ward, LC | 1 |
| Price, RI | 1 |
| Stewart, GO | 1 |
| Stuckey, BG | 1 |
| Prince, RL | 2 |
| Kent, GN | 2 |
| Bhagat, CI | 1 |
| Thompson, RI | 1 |
| Nicholson, GC | 1 |
| Terpos, E | 3 |
| Viniou, N | 3 |
| de la Fuente, J | 1 |
| Meletis, J | 3 |
| Voskaridou, E | 1 |
| Karkantaris, C | 1 |
| Vaiopoulos, G | 2 |
| Palermos, J | 3 |
| Yataganas, X | 3 |
| Goldman, JM | 1 |
| Rahemtulla, A | 1 |
| Wilkinson, JM | 3 |
| Stockley, I | 2 |
| Hamer, AJ | 2 |
| Barrington, NA | 2 |
| Eastell, R | 7 |
| Morabito, N | 1 |
| Gaudio, A | 1 |
| Lasco, A | 1 |
| Vergara, C | 1 |
| Tallarida, F | 1 |
| Crisafulli, G | 1 |
| Trifiletti, A | 1 |
| Cincotta, M | 1 |
| Pizzoleo, MA | 1 |
| Frisina, N | 1 |
| Pecherstorfer, M | 3 |
| Steinhauer, EU | 1 |
| Wetterwald, M | 1 |
| Bergström, B | 1 |
| Jackson, B | 1 |
| Mayahara, M | 1 |
| Sasaki, T | 1 |
| Elmann-Larsen, B | 1 |
| Schmitt, D | 1 |
| Bjarnason, NH | 1 |
| Haverbeke, G | 1 |
| Pertile, G | 1 |
| Claes, C | 1 |
| Zeyen, T | 1 |
| Herter-Clavel, C | 1 |
| Lubrano, A | 1 |
| Cundy, T | 2 |
| Wheadon, L | 1 |
| King, A | 1 |
| Kyrtsonis, MC | 1 |
| Vassilakopoulos, TP | 1 |
| Siakantaris, MP | 1 |
| Kokoris, SI | 1 |
| Gribabis, DA | 1 |
| Dimopoulou, MN | 1 |
| Angelopoulou, MK | 1 |
| Pangalis, GA | 1 |
| Wenzel, C | 1 |
| Bartsch, R | 1 |
| Hussian, D | 1 |
| Pluschnig, U | 1 |
| Locker, GJ | 1 |
| Sevelda, U | 1 |
| Zielinski, CC | 1 |
| Steger, GG | 1 |
| Kajiwara, H | 1 |
| Yamaza, T | 1 |
| Yoshinari, M | 1 |
| Goto, T | 1 |
| Iyama, S | 1 |
| Atsuta, I | 1 |
| Kido, MA | 1 |
| Tanaka, T | 1 |
| Cremers, SC | 2 |
| Lodder, MC | 1 |
| Den Hartigh, J | 2 |
| Vermeij, P | 5 |
| Van Pelt, P | 1 |
| Lems, WF | 1 |
| Dijkmans, BA | 2 |
| Wimalawansa, SJ | 1 |
| Kulkarni, G | 1 |
| Sherrard, DJ | 1 |
| Sanford, AP | 1 |
| Herndon, DN | 1 |
| Watanabe, Y | 1 |
| Ohshima, H | 2 |
| Mizuno, K | 1 |
| Sekiguchi, C | 2 |
| Fukunaga, M | 1 |
| Kohri, K | 1 |
| Rittweger, J | 2 |
| Felsenberg, D | 2 |
| Matsumoto, T | 2 |
| Nakamura, T | 2 |
| Munns, CF | 1 |
| Zeitlin, L | 1 |
| Fassier, F | 1 |
| Harvey, HA | 2 |
| Gralow, J | 1 |
| Frost, HM | 1 |
| Schiessl, H | 1 |
| Alkner, B | 1 |
| Tesch, P | 1 |
| Morony, S | 1 |
| Warmington, K | 1 |
| Adamu, S | 1 |
| Asuncion, F | 1 |
| Geng, Z | 1 |
| Grisanti, M | 1 |
| Tan, HL | 1 |
| Capparelli, C | 1 |
| Starnes, C | 1 |
| Weimann, B | 1 |
| Kostenuik, PJ | 1 |
| Vaisman, DN | 1 |
| McCarthy, AD | 1 |
| Cortizo, AM | 1 |
| Gelderblom, H | 1 |
| Seynaeve, C | 1 |
| van der Rijt, CC | 1 |
| van Zuylen, L | 1 |
| Munns, C | 1 |
| Land, C | 1 |
| Kananen, K | 1 |
| Volin, L | 1 |
| Laitinen, K | 1 |
| Ruutu, T | 1 |
| Välimäki, MJ | 1 |
| Barrick, M | 1 |
| Adamopoulos, IE | 1 |
| Wordsworth, PB | 1 |
| Edwards, JR | 1 |
| Ferguson, DJ | 1 |
| Athanasou, NA | 1 |
| Bhansali, A | 1 |
| Singh, R | 1 |
| Sriraam, M | 1 |
| Bhadada, S | 1 |
| Casolaro, M | 1 |
| Casolaro, I | 1 |
| Spreafico, A | 1 |
| Capperucci, C | 1 |
| Frediani, B | 1 |
| Marcolongo, R | 1 |
| Margiotta, N | 1 |
| Ostuni, R | 1 |
| Mendichi, R | 1 |
| Samperi, F | 1 |
| Ishii, T | 1 |
| Ito, Y | 1 |
| Griz, L | 1 |
| Colares, V | 1 |
| Bandeira, F | 1 |
| Keles, A | 1 |
| Grunes, B | 1 |
| Difuria, C | 1 |
| Gagari, E | 1 |
| Srinivasan, V | 1 |
| Darendeliler, MA | 1 |
| Muller, R | 1 |
| Kent, R | 1 |
| Stashenko, P | 1 |
| McKeage, K | 1 |
| Plosker, GL | 1 |
| Johansson, HR | 1 |
| Skripitz, R | 1 |
| Aspenberg, P | 1 |
| Tubiana-Hulin, M | 2 |
| Brière, M | 1 |
| Miravet, L | 2 |
| Clavel, B | 1 |
| Jung, A | 1 |
| Bornand, J | 1 |
| Mermillod, B | 1 |
| Edouard, C | 1 |
| Meunier, PJ | 1 |
| Reitsma, PH | 4 |
| Bijvoet, OL | 12 |
| Verlinden-Ooms, H | 1 |
| van der Wee-Pals, LJ | 4 |
| Adami, S | 1 |
| Frijlink, WB | 3 |
| O'Riordan, JL | 1 |
| Clemens, TL | 1 |
| van Breukelen, FJ | 2 |
| Sleeboom, HP | 2 |
| Mulder, H | 1 |
| van Oosterom, AT | 1 |
| Potokar, M | 1 |
| van Wijk-van Lennep, MM | 1 |
| Teitelbaum, SL | 2 |
| Kahn, AJ | 1 |
| Vismans, FJ | 1 |
| Selander, K | 1 |
| Lehenkari, P | 1 |
| Väänänen, HK | 1 |
| Purohit, OP | 4 |
| Radstone, CR | 1 |
| Anthony, C | 1 |
| Kanis, JA | 2 |
| Grant, J | 1 |
| Noble-Jamieson, G | 1 |
| Jamieson, N | 1 |
| Barnes, ND | 1 |
| Compston, JE | 3 |
| Azuma, Y | 1 |
| Sato, H | 1 |
| Oue, Y | 1 |
| Okabe, K | 1 |
| Ohta, T | 1 |
| Tsuchimoto, M | 1 |
| Kiyoki, M | 1 |
| Jagger, CJ | 2 |
| Chambers, TJ | 8 |
| Chow, JW | 4 |
| Kasra, M | 1 |
| Dumitriu, M | 1 |
| Nespeca, R | 1 |
| Very, JM | 1 |
| Mertz, BP | 1 |
| Eggelmeijer, F | 1 |
| van Paassen, HC | 1 |
| Breedveld, FC | 1 |
| Evans, CE | 1 |
| Braidman, IP | 1 |
| Rosen, HN | 5 |
| Dresner-Pollak, R | 2 |
| Moses, AC | 5 |
| Rosenblatt, M | 1 |
| Zeind, AJ | 2 |
| Clemens, JD | 1 |
| Greenspan, SL | 5 |
| Piper, K | 1 |
| Boyde, A | 1 |
| Jones, SJ | 1 |
| Devlin, RD | 1 |
| Fenton, AJ | 1 |
| Grill, V | 1 |
| Worth, GK | 1 |
| Hamdy, NA | 1 |
| Colwell, A | 1 |
| Russell, RG | 2 |
| Gallagher, A | 1 |
| Tobias, JH | 3 |
| Sullivan, EK | 1 |
| Middlebrooks, VL | 1 |
| Gundberg, C | 2 |
| Maitland, LA | 1 |
| Hock, JM | 1 |
| Brossard, JH | 1 |
| Garon, J | 1 |
| Lepage, R | 1 |
| Gascon-Barré, M | 1 |
| D'Amour, P | 1 |
| Redalieu, E | 1 |
| Coleman, JM | 1 |
| Chan, K | 1 |
| Seaman, J | 2 |
| Degen, PH | 1 |
| Flesch, G | 1 |
| Brox, A | 1 |
| Batiste, G | 1 |
| Abe, T | 2 |
| Lean, JM | 2 |
| Kung, VT | 1 |
| Seyedin, SM | 1 |
| Chen, T | 1 |
| Holick, M | 1 |
| Schweitzer, DH | 1 |
| Zwinderman, AH | 1 |
| Sahni, M | 1 |
| Guenther, HL | 1 |
| Fleisch, H | 3 |
| Collin, P | 1 |
| Martin, TJ | 1 |
| Bellingham, CM | 1 |
| Lee, JM | 1 |
| Moran, EL | 2 |
| Bogoch, ER | 1 |
| Selby, PL | 1 |
| Davies, M | 1 |
| Marks, JS | 1 |
| Mawer, EB | 1 |
| Erdtsieck, RJ | 1 |
| Pols, HA | 1 |
| Valk, NK | 1 |
| van Ouwerkerk, BM | 1 |
| Lamberts, SW | 1 |
| Mulder, P | 1 |
| Birkenhäger, JC | 1 |
| Dumon, JC | 2 |
| Piccart, M | 2 |
| Ford, J | 3 |
| Vinholes, J | 3 |
| Guo, CY | 2 |
| Gallagher, AC | 1 |
| Horowitz, SM | 2 |
| Algan, SA | 1 |
| Purdon, MA | 1 |
| Wattie, D | 1 |
| King, AR | 1 |
| Sauty, A | 1 |
| Zimmer-Roth, I | 1 |
| Fioroni, P | 1 |
| Juillerat, L | 1 |
| Markert, M | 1 |
| Ludwig, H | 1 |
| Leuenberger, P | 1 |
| Burckhardt, P | 4 |
| Thiebaud, D | 4 |
| Grauer, A | 1 |
| Klar, B | 1 |
| Knaus, J | 1 |
| Scharla, SH | 1 |
| Ziegler, R | 1 |
| Rogers, MJ | 1 |
| Chilton, KM | 1 |
| Coxon, FP | 1 |
| Lawry, J | 1 |
| Smith, MO | 1 |
| Suri, S | 1 |
| Van Beek, E | 3 |
| Löwik, C | 3 |
| Que, I | 1 |
| Papapoulos, S | 4 |
| Roldan, EJ | 2 |
| Kerzberg, EM | 1 |
| Castelli, G | 1 |
| Lloret, AP | 1 |
| Hiraga, T | 1 |
| Takada, M | 1 |
| Nakajima, T | 1 |
| Ozawa, H | 1 |
| Delmas, PD | 4 |
| Hortobagyi, GN | 1 |
| Theriault, RL | 1 |
| Porter, L | 2 |
| Blayney, D | 1 |
| Sinoff, C | 1 |
| Wheeler, H | 1 |
| Simeone, JF | 1 |
| Knight, RD | 1 |
| Ford, JF | 1 |
| Berenson, J | 2 |
| Theriault, R | 1 |
| Green, J | 1 |
| Licata, AA | 1 |
| Gineyts, E | 1 |
| Van Gelder, JM | 1 |
| Breuer, E | 2 |
| Schlossman, A | 1 |
| Ornoy, A | 2 |
| Mönkkönen, J | 1 |
| Similä, J | 1 |
| Klenner, T | 1 |
| Stadler, H | 1 |
| Krempien, B | 1 |
| Patlas, N | 2 |
| Golomb, G | 4 |
| Gonzales, JB | 1 |
| Fleisch, HA | 1 |
| McBride, G | 1 |
| King, LE | 1 |
| Tomlinson, G | 1 |
| Vieth, R | 1 |
| Bonde, M | 1 |
| Qvist, P | 1 |
| Kodama, Y | 1 |
| Nakayama, K | 1 |
| Fuse, H | 1 |
| Fukumoto, S | 1 |
| Kawahara, H | 1 |
| Kurokawa, T | 1 |
| Patashnik, S | 1 |
| Rabinovich, L | 1 |
| Kollerup, G | 1 |
| Sørensen, HA | 1 |
| Hyldstrup, L | 1 |
| Storm, T | 1 |
| Bembi, B | 1 |
| Parma, A | 1 |
| Bottega, M | 1 |
| Ceschel, S | 1 |
| Zanatta, M | 1 |
| Martini, C | 1 |
| Ciana, G | 1 |
| Martínez, ME | 1 |
| Del Campo, MT | 1 |
| Plaza, MA | 1 |
| Torrijos, A | 1 |
| Gijón, J | 1 |
| Grier, RL | 1 |
| Wise, GE | 1 |
| Brown, RJ | 1 |
| Watts, DJ | 1 |
| Löwik, CW | 5 |
| Vinholes, JJ | 1 |
| Abbey, ME | 1 |
| Coukell, AJ | 1 |
| Markham, A | 1 |
| Zanchetta, JR | 1 |
| Spivacow, RF | 1 |
| Bogado, C | 1 |
| Sarli, M | 1 |
| Devogelaer, JP | 1 |
| Nagant de Deuxchaisnes, C | 1 |
| Cohen, H | 1 |
| Solomon, V | 1 |
| Alferiev, IS | 1 |
| Eidelman, N | 1 |
| Hägele, G | 1 |
| Yaghoobian, J | 1 |
| Morieux, C | 2 |
| Denne, MA | 1 |
| Bouizar, Z | 1 |
| Ureña, P | 1 |
| Abildgaard, N | 1 |
| Rungby, J | 1 |
| Glerup, H | 1 |
| Brixen, K | 1 |
| Kassem, M | 1 |
| Brincker, H | 1 |
| Heickendorff, L | 1 |
| Eriksen, EF | 1 |
| Nielsen, JL | 1 |
| Loomer, PM | 1 |
| Ellen, RP | 1 |
| Tenenbaum, HC | 1 |
| Bishop, NJ | 2 |
| Chabot, G | 1 |
| Lanoue, G | 1 |
| Takamatsu, Y | 1 |
| Simmons, PJ | 1 |
| Moore, RJ | 1 |
| Morris, HA | 1 |
| To, LB | 1 |
| Lévesque, JP | 1 |
| Garber, J | 2 |
| Ross, DS | 2 |
| Lee, SL | 2 |
| Bartl, R | 1 |
| Diel, IJ | 1 |
| Kyle, RA | 1 |
| Mundy, GR | 1 |
| Paterson, AH | 1 |
| Rubens, RD | 3 |
| Shane, E | 1 |
| Rodino, MA | 1 |
| McMahon, DJ | 1 |
| Addesso, V | 1 |
| Staron, RB | 1 |
| Seibel, MJ | 1 |
| Mancini, D | 1 |
| Michler, RE | 1 |
| Lo, SH | 1 |
| Engler, H | 1 |
| Koeberle, D | 1 |
| Thuerlimann, B | 1 |
| Senn, HJ | 1 |
| Riesen, WF | 1 |
| Pieterman, E | 1 |
| Cohen, L | 1 |
| Kunzmann, V | 1 |
| Bauer, E | 1 |
| Wilhelm, M | 1 |
| Nance, PW | 1 |
| Schryvers, O | 1 |
| Leslie, W | 1 |
| Ludwig, S | 1 |
| Krahn, J | 1 |
| Uebelhart, D | 1 |
| Coleman, R | 1 |
| Lacombe, D | 1 |
| Rose, C | 1 |
| Bastit, P | 1 |
| Wildiers, J | 2 |
| Michel, J | 1 |
| Leonard, R | 1 |
| Nortier, J | 1 |
| Mignolet, F | 1 |
| Ninkovic, M | 2 |
| Alexander, GJ | 2 |
| Holmes, SD | 1 |
| Milligan, T | 1 |
| Price, C | 1 |
| Suzuki, M | 1 |
| Adachi, K | 1 |
| Sugimoto, T | 1 |
| Nakayama, H | 1 |
| Doi, K | 1 |
| Barişta, I | 1 |
| Major, PP | 1 |
| Hortobagyi, G | 1 |
| Derenne, S | 1 |
| Amiot, M | 1 |
| Barillé, S | 1 |
| Collette, M | 1 |
| Robillard, N | 1 |
| Berthaud, P | 1 |
| Bataille, R | 1 |
| Iloputaife, ID | 1 |
| Trombetti, A | 1 |
| Gerbase, MW | 1 |
| Spiliopoulos, A | 1 |
| Slosman, DO | 1 |
| Nicod, LP | 1 |
| Kapitola, J | 1 |
| Zák, J | 1 |
| Lacinová, Z | 1 |
| Justová, V | 1 |
| Tsionos, K | 1 |
| Anargyrou, K | 1 |
| Papassavas, P | 1 |
| Nam, JH | 1 |
| Moon, JI | 1 |
| Chung, SS | 1 |
| Kim, SI | 1 |
| Park, KI | 1 |
| Song, YD | 1 |
| Kim, KR | 1 |
| Lee, HC | 1 |
| Huh, K | 1 |
| Lim, SK | 1 |
| Fornasier, TL | 1 |
| Bogoch, TR | 1 |
| Peel, NF | 1 |
| Elson, RA | 1 |
| Rosen, LS | 1 |
| Howell, A | 1 |
| Morley, W | 1 |
| Dreicer, R | 1 |
| Kuross, SA | 1 |
| Seaman, JJ | 1 |
| Kraj, M | 1 |
| Pogłód, R | 1 |
| Pawlikowski, J | 1 |
| Maj, S | 1 |
| Nasiłowska, B | 1 |
| Yoon, TH | 1 |
| Lee, SH | 1 |
| Park, MH | 1 |
| Chung, JW | 1 |
| Kim, HJ | 1 |
| Vitale, G | 1 |
| Fonderico, F | 1 |
| Martignetti, A | 1 |
| Caraglia, M | 1 |
| Ciccarelli, A | 1 |
| Nuzzo, V | 1 |
| Abbruzzese, A | 1 |
| Lupoli, G | 1 |
| Clohisy, DR | 1 |
| O' Keefe, PF | 1 |
| Ramnaraine, ML | 1 |
| Smith, MR | 1 |
| McGovern, FJ | 1 |
| Zietman, AL | 1 |
| Fallon, MA | 1 |
| Hayden, DL | 1 |
| Schoenfeld, DA | 1 |
| Kantoff, PW | 1 |
| Finkelstein, JS | 1 |
| Dawson-Hughes, B | 1 |
| Jagdev, SP | 1 |
| Purohit, P | 1 |
| Heatley, S | 1 |
| Herling, C | 1 |
| Cremers, S | 1 |
| Sparidans, R | 1 |
| den, HJ | 1 |
| Hamdy, N | 1 |
| Chen, B | 1 |
| Nierman, DM | 1 |
| Stein, A | 1 |
| Gray, AW | 1 |
| Davies, ME | 1 |
| Jeffcott, LB | 1 |
| Vedi, S | 1 |
| Garrahan, NJ | 1 |
| Kim, YH | 1 |
| Kim, GS | 1 |
| Jeong-Hwa, B | 1 |
| Eitan, Y | 1 |
| Hoffman, A | 1 |
| van der Pluijm, G | 2 |
| Binderup, L | 1 |
| Bramm, E | 1 |
| van der Wee-Pals, L | 1 |
| De Groot, H | 2 |
| Binderup, E | 1 |
| Houston, S | 1 |
| James, I | 1 |
| Rodger, A | 1 |
| Leonard, RC | 1 |
| Fitton, A | 1 |
| McTavish, D | 1 |
| Chow, J | 1 |
| Colston, KW | 1 |
| Clarke, NW | 1 |
| McClure, J | 1 |
| George, NJ | 1 |
| Mitlak, BH | 1 |
| Rodda, CP | 1 |
| Von Deck, MD | 1 |
| Dobrolet, NC | 1 |
| Neer, RM | 1 |
| Nussbaum, SR | 1 |
| Mallmin, H | 1 |
| Ljunghall, S | 1 |
| Larsson, K | 1 |
| Lindh, E | 1 |
| Leyvraz, S | 1 |
| von Fliedner, V | 1 |
| Perey, L | 1 |
| Cornu, P | 1 |
| Thiébaud, S | 1 |
| Mühlbauer, RC | 1 |
| Bauss, F | 1 |
| Schenk, R | 1 |
| Janner, M | 1 |
| Bosies, E | 1 |
| Strein, K | 1 |
| Alblas, MJ | 1 |
| Flanagan, AM | 1 |
| Netelenbos, JC | 1 |
| van Ginkel, FC | 1 |
| Lips, P | 1 |
| Leeuwenkamp, OR | 1 |
| Barto, R | 1 |
| van der Vijgh, WJ | 1 |
| van der Wiel, H | 1 |
| Hackeng, WH | 1 |
| Hoekman, K | 2 |
| Tjandra, YI | 1 |
| Carano, A | 1 |
| Konsek, JD | 1 |
| Schlesinger, PH | 1 |
| Blair, HC | 1 |
| Sato, M | 1 |
| Grasser, W | 1 |
| Nishijima, Y | 1 |
| Nemoto, R | 1 |
| Koiso, K | 1 |
| Pelger, RC | 1 |
| Lycklama à Nijeholt, AA | 1 |
| Ralston, SH | 2 |
| Gallacher, SJ | 1 |
| Patel, U | 1 |
| Dryburgh, FJ | 1 |
| Fraser, WD | 1 |
| Cowan, RA | 1 |
| Boyle, IT | 2 |
| Magritte, A | 1 |
| Seraj, F | 1 |
| Sculier, JP | 1 |
| Borkowski, A | 1 |
| Jaeger, P | 1 |
| Jacquet, AF | 1 |
| Boonekamp, PM | 2 |
| van de Pluym, G | 1 |
| van de Wee-Pals, L | 1 |
| Bloys van Treslong-de Groot, H | 1 |
| Lerner, UH | 1 |
| Larsson, A | 1 |
| Delaissé, JM | 1 |
| Eeckhout, Y | 1 |
| Vaes, G | 1 |
| Warrell, RP | 1 |
| Reid, IR | 1 |
| Katz, JM | 1 |
| Ibbertson, HK | 1 |
| Gray, DH | 1 |
| Alzaid, AA | 1 |
| Gardner, MD | 1 |
| Maldague, B | 1 |
| Malghem, J | 1 |
| Pointillart, A | 1 |
| Bergot, C | 1 |
| Bielakoff, J | 1 |
| Laval Jeantet, AM | 1 |
| Stutzmann, JJ | 1 |
| Petrovic, AG | 1 |
| Harinck, HI | 1 |
| Plantingh, AS | 1 |
| Elte, JW | 1 |
| Neijt, JP | 1 |
| van Wijk-van Lennep, ML | 1 |
| Marie, PJ | 2 |
| Hott, M | 2 |
| Garba, MT | 2 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II Study of Bone Marker Assessment of Multiple Myeloma Patients Treated With AminoBisphosphonates[NCT00577642] | Phase 2 | 29 participants (Actual) | Interventional | 2007-10-31 | Completed | ||
| A 2 Year Prospective, Multicentre, Open-label, Randomised, Controlled Study to Investigate the Effectiveness of Pamidronate in the Prevention of Bone Loss in de Novo Renal Transplant Patients (With a PTH > 150pg/ml) on a Ciclosporin A and Glucocorticoid B[NCT00738257] | Phase 4 | 126 participants (Actual) | Interventional | 2000-06-30 | Completed | ||
| Simulation of a Mission Aboard the International Space Station by a Long Duration Anti-Orthostatic Bed Confinement at - 6° (90 Days) on Healthy Subjects:1/Perfecting of Preventive Methods (Muscular Exercise and Biphosphonates) and Evaluation of the Effect[NCT00311571] | Phase 1 | 28 participants | Interventional | 2001-08-31 | Completed | ||
| Bone Retention of Bisphosphonate (Zometa) in Patients With Multiple Myeloma or Breast Cancer With Metastases to Bone[NCT00760370] | Phase 2 | 60 participants (Actual) | Interventional | 2008-12-31 | Completed | ||
| Prevention of Bone Loss After Pediatric Hematopoietic Cell Transplantation[NCT02074631] | Phase 2 | 80 participants (Actual) | Interventional | 2015-02-28 | Completed | ||
| A Phase I Pilot Trial to Study the Safety and Efficacy of Concomitant Radiotherapy and Zoledronic Acid for the Palliation of Bone Metastases From Breast Cancer, Prostate Cancer and Lung Cancer[NCT00264420] | Phase 1 | 4 participants (Actual) | Interventional | 2005-12-31 | Completed | ||
| Bone Biopsy for Histomorphometry and Analysis of Bone Marrow Derived Osteoblast and Osteoclast Progenitors to Explore Mechanisms of Decreased Bone Mineral Density in Depression[NCT00001916] | 17 participants | Observational | 1999-03-31 | Completed | |||
| Osteoporosis in Cystic Fibrosis: Study of Bone Mass and Bone Metabolism, and Prospective Randomized Therapeutic Trial.[NCT01812551] | Phase 3 | 171 participants (Actual) | Interventional | 2002-10-31 | Completed | ||
| A 1-year, Multicenter, Open-label Extension to CZOL446H2337 to Evaluate Safety and Efficacy of Zoledronic Acid Twice Yearly in Osteoporotic Children Treated With Glucocorticoids[NCT01197300] | Phase 3 | 25 participants (Actual) | Interventional | 2010-10-25 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Vertebral morphometry (or concave index) was calculated using the average ratio between mid-height and posterior height from L1 to L4 and performed by a central reader. A new morphometric vertebral fractures during the 12 month Extension Period was defined as a morphometric vertebral fracture present at Month 24 X-ray which was not present at the Extension Baseline (Baseline 2). (NCT01197300)
Timeframe: Month 24 (Visit 15/Final Extension Visit)
| Intervention | Participants (Count of Participants) |
|---|---|
| Core Treatment Zoledronic Acid | 1 |
| Core Treatment: Placebo | 1 |
New vertebral fractures are defined as fractures of Genant grade 1 or higher that occur at lumbar or thoracic spine from first extension dose infusion to the end of the study in a previously normal vertebra. (NCT01197300)
Timeframe: Month 24 (Visit 15/Final Extension Visit)
| Intervention | Participants (Count of Participants) |
|---|---|
| Core Treatment Zoledronic Acid | 1 |
| Core Treatment: Placebo | 1 |
Analysis of absolute and relative frequencies for treatment emergent Adverse Event (AE), Serious Adverse Event (SAE) and Deaths by primary System Organ Class (SOC) to demonstrate that zoledronic acid given long-term, over an additional 12 months from the Core study (CZOL446H2337), is safe for the treatment of osteoporotic children treated with glucocorticoids through the monitoring of relevant clinical and laboratory safety parameters. (NCT01197300)
Timeframe: Baseline 1 (Visit 1 of the Core Study) through Month 24 (Visit 15/Final Extension Visit)
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| On-treatment Adverse Events (AEs) | On-treatment Serious Adverse Events (SAEs) | On-treatment Deaths | |
| Core Treatment Zoledronic Acid | 7 | 3 | 0 |
| Core Treatment: Placebo | 12 | 0 | 0 |
Left postero-anterior (PA) hand/wrist X-ray were taken at the final visit of Core study and at Visit 15/EOS (Month 24) to assess bone age. The change in 2nd metacarpal cortical width at Month 24 relative to the respective Baseline was calculated. If a fracture of the left upper extremity precluded radiographic imaging, (or precluded this X-ray in the Core study) then the right hand was evaluated for this purpose. In this case, an image of the right hand was carried out at both Visit 8 and at Visit 15/EOS (Month 24). The information was used in the assessment of bone density. (NCT01197300)
Timeframe: Baseline 1 (Visit 1 of the Core Study) and Baseline 2 (Visit 9 of the Extension Study) through Month 24 (Visit 15/Final Extension Visit)
| Intervention | millimeter (mm) (Least Squares Mean) | |
|---|---|---|
| 2nd metacarpal cortical width change from BL1 | 2nd metacarpal cortical width change from BL2 | |
| Core Treatment Zoledronic Acid | -0.04 | -0.09 |
| Core Treatment: Placebo | -0.03 | 0.02 |
Bone specific alkaline phosphatase (BSAP) was collected at the final visit Core study at Visit 8, or at 1st infusion visit (Visit 9), and thereafter at Visit 12 (Month 18) and Visit 15 (Month 24) (final Extension study Visit/EOS) of Extension study according to the instructions provided in the Laboratory Manual. The samples were analyzed in batches at the laboratory. Decrease or negative changes from Core baseline indicated a pharmacological response to therapy. (NCT01197300)
Timeframe: Month 18 (Visit 12 of the Extension Study), Month 24 (Visit 15/Final Extension Visit)
| Intervention | nanogram per milliliter (ng/mL) (Least Squares Mean) | |
|---|---|---|
| BSAP Change at Month 18 | BSAP Change at Month 24 | |
| Core Treatment Zoledronic Acid | -13.716 | -9.675 |
| Core Treatment: Placebo | 3.975 | -6.013 |
Lumbar Spine Bone Mineral Content (BMC) was determined by the central imaging vendor at the final visit of Core study (Visit 8) or at 1st infusion visit (Visit 9), and thereafter at Visit 12 (Month 18) and Visit 15 (Month 24) (final Extension Study visit/EOS) of Extension study. The methods to be used to measure BMC were described in the respective DXA Manuals. Positive changes from Core baseline indicated an improvement in condition. (NCT01197300)
Timeframe: Month 18 (Visit 12 of the Extension Study), Month 24 (Visit 15/Final Extension Visit)
| Intervention | gram (Least Squares Mean) | |
|---|---|---|
| Lumbar Spine BMC Change at Month 18 | Lumbar Spine BMC Change at Month 24 | |
| Core Treatment Zoledronic Acid | 12.293 | 15.845 |
| Core Treatment: Placebo | 9.933 | 14.666 |
Lumbar Spine Bone Mineral Density (BMD) Z-score was determined by the central imaging vendor at the final visit of Core study (Visit 8) or at 1st infusion visit (Visit 9), and thereafter at Visit 12 (Month 18) and Visit 15 (Month 24) (final Extension Study visit/EOS) of Extension study. The methods to be used to measure Lumbar Spine BMD Z-score were described in the respective DXA Manuals provided by central imaging vendor. Positive changes from Core baseline indicated an improvement in condition. (NCT01197300)
Timeframe: Month 18 (Visit 12 of the Extension Study), Month 24 (Visit 15/Final Extension Visit)
| Intervention | Z-score (Least Squares Mean) | |
|---|---|---|
| Lumbar Spine BMD Z-score Change at Month 18 | Lumbar Spine BMD Z-score Change at Month 24 | |
| Core Treatment Zoledronic Acid | -40.648 | -46.161 |
| Core Treatment: Placebo | -44.348 | -67.913 |
Serum Cross linked N-telopeptide (NTX) was collected at the final visit Core study at Visit 8, or at 1st infusion visit (Visit 9), and thereafter at Visit 12 (Month 18) and Visit 15 (Month 24) (final Extension study Visit/EOS) of Extension study according to the instructions provided in the Laboratory Manual. The samples were analyzed in batches at the laboratory. Decrease or negative changes from Core baseline indicated a pharmacological response to therapy. (NCT01197300)
Timeframe: Month 18 (Visit 12 of the Extension Study), Month 24 (Visit 15/Final Extension Visit)
| Intervention | nmol BCE/L (Least Squares Mean) | |
|---|---|---|
| Serum NTX Change at Month 18 | Serum NTX Change at Month 24 | |
| Core Treatment Zoledronic Acid | -17.577 | -17.450 |
| Core Treatment: Placebo | -12.916 | -14.891 |
Serum Procollagen type 1 amino-terminal propeptide (P1NP) was collected at the final visit Core study at Visit 8, or at 1st infusion visit (Visit 9), and thereafter at Visit 12 (Month 18) and Visit 15 (Month 24) (final Extension study Visit/EOS) of Extension study according to the instructions provided in the Laboratory Manual. The samples were analyzed in batches at the laboratory. Decrease or negative changes from Core baseline indicated a pharmacological response to therapy. (NCT01197300)
Timeframe: Month 18 (Visit 12 of the Extension Study), Month 24 (Visit 15/Final Extension Visit)
| Intervention | nanogram per milliliter (ng/mL) (Least Squares Mean) | |
|---|---|---|
| Serum P1NP Change at Month 18 | Serum P1NP Change at Month 24 | |
| Core Treatment Zoledronic Acid | -169.837 | -228.068 |
| Core Treatment: Placebo | -22.157 | -95.631 |
Serum Tartrate-resistant acid phosphatase isoform 5b (TRAP 5b) were collected at the final visit Core study at Visit 8, or at 1st infusion visit (Visit 9), and thereafter at Visit 12 (Month 18) and Visit 15 (Month 24) (final Extension study Visit/EOS) of Extension study according to the instructions provided in the Laboratory Manual. The samples were analyzed in batches at the laboratory. Decrease or negative changes from Core baseline indicated a pharmacological response to therapy. Decrease or negative changes from Core baseline indicated a pharmacological response to therapy. (NCT01197300)
Timeframe: Month 18 (Visit 12 of the Extension Study), Month 24 (Visit 15/Final Extension Visit)
| Intervention | U/L (Least Squares Mean) | |
|---|---|---|
| Serum TRAP-5b Change at Month 18 | Serum TRAP-5b Change at Month 24 | |
| Core Treatment Zoledronic Acid | -2.661 | -2.670 |
| Core Treatment: Placebo | -1.179 | -2.260 |
Total body BMC were determined by the central imaging vendor at the final visit of Core study (Visit 8) or at 1st infusion visit (Visit 9), and thereafter at Visit 12 (Month 18) and Visit 15 (Month 24) (final Extension Study visit/EOS) of Extension study. The methods to be used to measure BMC were described in the respective DXA Manuals. Positive changes from Core baseline indicated an improvement in condition. (NCT01197300)
Timeframe: Month 18 (Visit 12 of the Extension Study), Month 24 (Visit 15/Final Extension Visit)
| Intervention | gram (Least Squares Mean) | |
|---|---|---|
| Total body BMC Change at Month 18 | Total body BMC Change at Month 24 | |
| Core Treatment Zoledronic Acid | 387.721 | 496.997 |
| Core Treatment: Placebo | 266.592 | 431.323 |
Pain was evaluated at each visit (at office and telephone visit) at the final visit of the Core study and first visit of the Extension study (Visit 9), Visits 11 (Month 15), 12 (Month 18), 14 (Month 21) and 15 (Month 24) using the Faces Pain Scale-Revised (FPS-R). Children were selecting the face that best fits their pain. The pain score ranged from 0 (No Pain) to 10 (Very Much Pain). The reduction in pain from Core baseline by visit was evaluated based on whether or not patients had a decrease in their FPS-R from baseline. If pain remained the same or worsened from baseline a patient was classified as '0' and if the pain scale decreased then the patient was classified as '1'. (NCT01197300)
Timeframe: Month 15, Month 18, Month 21, Month 24
| Intervention | Percentage of Patients (Number) | |||
|---|---|---|---|---|
| Reduction in Pain at Month 15 | Reduction in Pain at Month 18 | Reduction in Pain at Month 21 | Reduction in Pain at Month 24 | |
| Core Treatment Zoledronic Acid | 55.6 | 30.0 | 30.0 | 30.0 |
| Core Treatment: Placebo | 46.2 | 50.0 | 50.0 | 38.5 |
26 reviews available for pamidronate and Bone Loss, Osteoclastic
| Article | Year |
|---|---|
Pamidronate: A model compound of the pharmacology of nitrogen-containing bisphosphonates; A Leiden historical perspective.
Topics: Bone Resorption; Diphosphonates; Humans; Nitrogen; Pamidronate | 2020 |
Acute hypercalcemia and excessive bone resorption following anti-RANKL withdrawal: Case report and brief literature review.
Topics: Acute Disease; Bone and Bones; Bone Resorption; Female; Humans; Hypercalcemia; Middle Aged; Pamidron | 2019 |
Crosstalk between bone niche and immune system: osteoimmunology signaling as a potential target for cancer treatment.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bone and Bones; Bone Density Cons | 2015 |
The use of zoledronic acid, a novel, highly potent bisphosphonate, for the treatment of hypercalcemia of malignancy.
Topics: Anti-Inflammatory Agents; Bone Resorption; Diphosphonates; Dose-Response Relationship, Drug; Humans; | 2002 |
Advances in the biology and treatment of myeloma bone disease.
Topics: Bone Resorption; Boronic Acids; Bortezomib; Carrier Proteins; Clinical Trials as Topic; Cytokines; D | 2002 |
Treatment of hypercalcemia of malignancy with bisphosphonates.
Topics: Bone Resorption; Clinical Trials as Topic; Clodronic Acid; Diphosphonates; Etidronic Acid; Humans; H | 2002 |
Treatment of idiopathic hyperphosphatasia with intensive bisphosphonate therapy.
Topics: Alkaline Phosphatase; Audiometry, Pure-Tone; Biomarkers; Biopsy; Bone Conduction; Bone Density; Bone | 2004 |
Optimizing bisphosphonate therapy in patients with breast cancer on endocrine therapy.
Topics: Antineoplastic Agents; Aromatase Inhibitors; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Clin | 2004 |
Evolving role of bisphosphonates in women undergoing treatment for localized and advanced breast cancer.
Topics: Antineoplastic Agents; Aromatase Inhibitors; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Chem | 2005 |
New therapeutic agents for the treatment of bone diseases.
Topics: Antineoplastic Agents; Bone Density Conservation Agents; Bone Diseases; Bone Diseases, Metabolic; Bo | 2005 |
[Treatment of Paget's disease of bone: importance of the zoledronic acid].
Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Resorption; Calcitonin; Dipho | 2006 |
Treatment of osteogenesis imperfecta: who, why, what?
Topics: Age Factors; Bone Density Conservation Agents; Bone Remodeling; Bone Resorption; Child, Preschool; D | 2007 |
Zoledronic acid: a pharmacoeconomic review of its use in the management of bone metastases.
Topics: Administration, Oral; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Breast Neop | 2008 |
Bisphosphonate therapy.
Topics: Alendronate; Animals; Bone Density; Bone Resorption; Clodronic Acid; Diphosphonates; Etidronic Acid; | 1997 |
Use of bisphosphonates in cancer patients.
Topics: Alendronate; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Clodronic Acid; Diphosphonates; Etid | 1996 |
Bisphosphonates: preclinical aspects and use in osteoporosis.
Topics: Alendronate; Animals; Bone Resorption; Clodronic Acid; Diphosphonates; Etidronic Acid; Humans; Osteo | 1997 |
Bisphosphonates and breast carcinoma.
Topics: Bone Diseases; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Calcification, Physiologic; Clinic | 1997 |
Bisphosphonates in multiple myeloma.
Topics: Bone Diseases; Bone Resorption; Clodronic Acid; Diphosphonates; Etidronic Acid; Humans; Multiple Mye | 1997 |
Pamidronate. A review of its use in the management of osteolytic bone metastases, tumour-induced hypercalcaemia and Paget's disease of bone.
Topics: Antineoplastic Agents; Bone Neoplasms; Bone Resorption; Diphosphonates; Humans; Hypercalcemia; Neopl | 1998 |
Aredia: the once-monthly infusion for the treatment of bone metastases.
Topics: Antineoplastic Agents; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Clinical Trials as Topic; | 1998 |
Current use of bisphosphonates in oncology. International Bone and Cancer Study Group.
Topics: Analgesics, Non-Narcotic; Bone and Bones; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Clodron | 1998 |
Oral bisphosphonates: A review of clinical use in patients with bone metastases.
Topics: Alendronate; Biological Availability; Bone Density; Bone Neoplasms; Bone Resorption; Breast Neoplasm | 2000 |
Bone metastases and tumor-induced hypercalcemia.
Topics: Antineoplastic Agents; Bone Neoplasms; Bone Resorption; Calcitonin; Combined Modality Therapy; Dipho | 1992 |
Pamidronate. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease.
Topics: Animals; Bone Resorption; Diphosphonates; Drug Evaluation; Humans; Hypercalcemia; Osteitis Deformans | 1991 |
Bone metastases and breast cancer.
Topics: Alkaline Phosphatase; Bone and Bones; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Calcium-Bin | 1985 |
Dynamic radiologic patterns of Paget's disease of bone.
Topics: Biomechanical Phenomena; Bone and Bones; Bone Development; Bone Resorption; Calcitonin; Diphosphonat | 1987 |
59 trials available for pamidronate and Bone Loss, Osteoclastic
| Article | Year |
|---|---|
Burn injury and restoration of muscle function.
Topics: Animals; Bone Resorption; Child; Diphosphonates; Humans; Mice; Muscle Proteins; Muscular Atrophy; Pa | 2020 |
Pamidronate in the prevention of bone loss after liver transplantation: a randomized controlled trial.
Topics: Adult; Aged; Bone Density; Bone Density Conservation Agents; Bone Resorption; Diphosphonates; Double | 2009 |
Effect of pamidronate on bone loss after kidney transplantation: a randomized trial.
Topics: Absorptiometry, Photon; Adolescent; Adult; Aged; Bone Density Conservation Agents; Bone Resorption; | 2009 |
A comparative study of intravenous ibandronate and pamindronate in patients with bone metastases from breast or lung cancer: effect on metastatic bone pain.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Diphosphonates; | 2011 |
Prospective study of histomorphometry, biochemical bone markers and bone densitometric response to pamidronate in β-thalassaemia presenting with osteopenia-osteoporosis syndrome.
Topics: Adolescent; Adult; beta-Thalassemia; Biomarkers; Bone and Bones; Bone Density; Bone Diseases, Metabo | 2012 |
Bone turnover in children and adolescents with McCune-Albright syndrome treated with pamidronate for bone fibrous dysplasia.
Topics: Adolescent; Adult; Alkaline Phosphatase; Anti-Inflammatory Agents; Bone and Bones; Bone Density; Bon | 2002 |
A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases.
Topics: Antineoplastic Agents; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Diphosphonates; Dose-Respo | 2003 |
Bone density changes in Paget's disease 2 years after iv pamidronate: profound, sustained increases in pagetic bone with severity-related loss in forearm nonpagetic cortical bone.
Topics: Aged; Analysis of Variance; Bone Density; Bone Resorption; Diphosphonates; Female; Follow-Up Studies | 2003 |
Pamidronate is superior to ibandronate in decreasing bone resorption, interleukin-6 and beta 2-microglobulin in multiple myeloma.
Topics: Acid Phosphatase; Aged; Antineoplastic Agents; beta 2-Microglobulin; Biomarkers; Bone Resorption; Co | 2003 |
Biochemical markers of bone turnover and development of heterotopic ossification after total hip arthroplasty.
Topics: Adult; Aged; Anti-Inflammatory Agents; Arthroplasty, Replacement, Hip; Biomarkers; Bone Resorption; | 2003 |
Three-year effectiveness of intravenous pamidronate versus pamidronate plus slow-release sodium fluoride for postmenopausal osteoporosis.
Topics: Alkaline Phosphatase; Bone Density; Bone Resorption; Calcium; Diphosphonates; Drug Therapy, Combinat | 2003 |
Efficacy and safety of ibandronate in the treatment of hypercalcemia of malignancy: a randomized multicentric comparison to pamidronate.
Topics: Administration, Oral; Aged; Anti-Inflammatory Agents; Bone Resorption; Diphosphonates; Female; Human | 2003 |
Effect of pamidronate on excretion of pyridinium crosslinks of collagen after total hip arthroplasty.
Topics: Anti-Inflammatory Agents; Arthroplasty, Replacement, Hip; Biomarkers; Bone Resorption; Collagen; Col | 2003 |
Short term whole body retention in relation to rate of bone resorption and cartilage degradation after intravenous bisphosphonate (pamidronate) in rheumatoid arthritis.
Topics: Adult; Aged; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Biomarkers; Bone Resorption; Cartilage | 2004 |
The efficacy of acute administration of pamidronate on the conservation of bone mass following severe burn injury in children: a double-blind, randomized, controlled study.
Topics: Absorptiometry, Photon; Acute Disease; Adolescent; Amino Acids; Anti-Inflammatory Agents; Biomarkers | 2005 |
Intravenous pamidronate prevents femoral bone loss and renal stone formation during 90-day bed rest.
Topics: Adult; Alkaline Phosphatase; Bed Rest; Biomarkers; Bone and Bones; Bone Density; Bone Diseases, Meta | 2004 |
Muscle atrophy and bone loss after 90 days' bed rest and the effects of flywheel resistive exercise and pamidronate: results from the LTBR study.
Topics: Adult; Aerospace Medicine; Alkaline Phosphatase; Amino Acids; Bed Rest; Bone Density; Bone Resorptio | 2005 |
Pamidronate in children and adolescents with osteogenesis imperfecta: effect of treatment discontinuation.
Topics: Adolescent; Adult; Biomarkers; Bone and Bones; Bone Density; Bone Density Conservation Agents; Bone | 2006 |
Serum osteoprotegerin and receptor activator of nuclear factor-kappaB ligand (RANKL) concentrations in allogeneic stem cell transplant-recipients: a role in bone loss?
Topics: Absorptiometry, Photon; Adult; Bone Density; Bone Density Conservation Agents; Bone Resorption; Case | 2006 |
A randomised double-blind comparison of intravenous pamidronate and clodronate in the hypercalcaemia of malignancy.
Topics: Bone Neoplasms; Bone Resorption; Clodronic Acid; Diphosphonates; Double-Blind Method; Humans; Hyperc | 1995 |
Clinical and biochemical response to single infusion of pamidronate in patients with active rheumatoid arthritis: a double blind placebo controlled study.
Topics: Adult; Arthritis, Rheumatoid; Bone and Bones; Bone Resorption; Calcium; Diphosphonates; Double-Blind | 1994 |
Specificity of urinary excretion of cross-linked N-telopeptides of type I collagen as a marker of bone turnover.
Topics: Adolescent; Adult; Amino Acids; Analysis of Variance; Biomarkers; Bone Resorption; Calcium; Collagen | 1994 |
Urinary excretion of aminohydroxypropylidene bisphosphonate in cancer patients after single intravenous infusions.
Topics: Adult; Aged; Bone Resorption; Chromatography, High Pressure Liquid; Diphosphonates; Female; Humans; | 1993 |
Therapy with parenteral pamidronate prevents thyroid hormone-induced bone turnover in humans.
Topics: Adolescent; Adult; Amino Acids; Bone Resorption; Calcitriol; Calcium; Creatinine; Diphosphonates; Hu | 1993 |
Treatment of post-menopausal osteoporosis with a combination of growth hormone and pamidronate: a placebo controlled trial.
Topics: Aged; Body Composition; Bone Density; Bone Resorption; Diphosphonates; Drug Therapy, Combination; Fe | 1995 |
Intravenous pamidronate in patients with tumor-induced osteolysis: a biochemical dose-response study.
Topics: Adult; Aged; Analysis of Variance; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Calcitriol; Ca | 1995 |
Metabolic effects of pamidronate in patients with metastatic bone disease.
Topics: Aged; Alkaline Phosphatase; Analysis of Variance; Biomarkers; Bone Development; Bone Neoplasms; Bone | 1996 |
The role of bisphosphonates in the treatment of bone metastases--the U.S. experience.
Topics: Antineoplastic Agents; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Clinical Trials as Topic; | 1996 |
Interleukin-6 and tumor necrosis factor alpha levels after bisphosphonates treatment in vitro and in patients with malignancy.
Topics: Aged; Aged, 80 and over; Bone Resorption; Clodronic Acid; Diphosphonates; Female; Follow-Up Studies; | 1996 |
[Bisphosphonate therapy of Paget's disease of bone with pamidronate].
Topics: Aged; Bone Resorption; Diphosphonates; Dose-Response Relationship, Drug; Drug Administration Schedul | 1996 |
Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group.
Topics: Antineoplastic Agents; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Diphosphonates; Disease-Fr | 1996 |
Pamidronate in the treatment of osteolytic bone metastases in breast cancer patients.
Topics: Bone Neoplasms; Bone Resorption; Breast Neoplasms; Diphosphonates; Female; Humans; Hypercalcemia; Pa | 1996 |
Evaluation of new bone resorption markers in a randomized comparison of pamidronate or clodronate for hypercalcemia of malignancy.
Topics: Adult; Aged; Aged, 80 and over; Amino Acids; Biomarkers; Bone Neoplasms; Bone Resorption; Calcium; C | 1997 |
Assessment of different markers of bone resorption in postmenopausal osteoporotic women treated with pamidronate.
Topics: Aged; Amino Acids; Biomarkers; Bone Resorption; Chromatography, High Pressure Liquid; Diphosphonates | 1997 |
Bisphosphonates in multiple myeloma.
Topics: Bone Diseases; Bone Resorption; Clodronic Acid; Diphosphonates; Etidronic Acid; Humans; Multiple Mye | 1997 |
Pamidronate and biochemical markers of bone turnover.
Topics: Acid Phosphatase; Adult; Aged; Amino Acids; Biomarkers; Bone and Bones; Bone Resorption; Calcitriol; | 1997 |
Relationships between biochemical and symptomatic response in a double-blind randomised trial of pamidronate for metastatic bone disease.
Topics: Adult; Aged; Bone Neoplasms; Bone Resorption; Diphosphonates; Double-Blind Method; Female; Humans; M | 1997 |
Long-term oral pamidronate treatment inhibits osteoclastic bone resorption and bone turnover without affecting osteoblastic function in multiple myeloma.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers; Bone and Bones; Bo | 1998 |
Cyclic administration of pamidronate in children with severe osteogenesis imperfecta.
Topics: Adolescent; Alkaline Phosphatase; Bone Density; Bone Development; Bone Resorption; Calcium; Child; C | 1998 |
Cyclic administration of pamidronate in children with severe osteogenesis imperfecta.
Topics: Adolescent; Alkaline Phosphatase; Bone Density; Bone Development; Bone Resorption; Calcium; Child; C | 1998 |
Cyclic administration of pamidronate in children with severe osteogenesis imperfecta.
Topics: Adolescent; Alkaline Phosphatase; Bone Density; Bone Development; Bone Resorption; Calcium; Child; C | 1998 |
Cyclic administration of pamidronate in children with severe osteogenesis imperfecta.
Topics: Adolescent; Alkaline Phosphatase; Bone Density; Bone Development; Bone Resorption; Calcium; Child; C | 1998 |
Cyclic administration of pamidronate in children with severe osteogenesis imperfecta.
Topics: Adolescent; Alkaline Phosphatase; Bone Density; Bone Development; Bone Resorption; Calcium; Child; C | 1998 |
Cyclic administration of pamidronate in children with severe osteogenesis imperfecta.
Topics: Adolescent; Alkaline Phosphatase; Bone Density; Bone Development; Bone Resorption; Calcium; Child; C | 1998 |
Cyclic administration of pamidronate in children with severe osteogenesis imperfecta.
Topics: Adolescent; Alkaline Phosphatase; Bone Density; Bone Development; Bone Resorption; Calcium; Child; C | 1998 |
Cyclic administration of pamidronate in children with severe osteogenesis imperfecta.
Topics: Adolescent; Alkaline Phosphatase; Bone Density; Bone Development; Bone Resorption; Calcium; Child; C | 1998 |
Cyclic administration of pamidronate in children with severe osteogenesis imperfecta.
Topics: Adolescent; Alkaline Phosphatase; Bone Density; Bone Development; Bone Resorption; Calcium; Child; C | 1998 |
Utility of biochemical markers of bone turnover in the follow-up of patients treated with bisphosphonates.
Topics: Alkaline Phosphatase; Amino Acids; Antineoplastic Agents; Biomarkers; Bone and Bones; Bone Resorptio | 1998 |
Intravenous pamidronate attenuates bone density loss after acute spinal cord injury.
Topics: Acute Disease; Bone and Bones; Bone Density; Bone Resorption; Collagen; Collagen Type I; Diphosphona | 1999 |
Changes in calcium homoeostasis in patients undergoing liver transplantation: effects of a single infusion of pamidronate administered pre-operatively.
Topics: Adult; Aged; Anti-Inflammatory Agents; Bone Resorption; Calcium; Diphosphonates; Female; Homeostasis | 1999 |
Serum CTX: a new marker of bone resorption that shows treatment effect more often than other markers because of low coefficient of variability and large changes with bisphosphonate therapy.
Topics: Anti-Inflammatory Agents; Biomarkers; Bone Density; Bone Resorption; Collagen; Collagen Type I; Diph | 2000 |
Bone mineral density in lung-transplant recipients before and after graft: prevention of lumbar spine post-transplantation-accelerated bone loss by pamidronate.
Topics: Adolescent; Adult; Anti-Inflammatory Agents; Bone Density; Bone Resorption; Calcium; Dietary Supplem | 2000 |
Effect of pamidronate administration on markers of bone turnover and disease activity in multiple myeloma.
Topics: Aged; Alkaline Phosphatase; Antineoplastic Combined Chemotherapy Protocols; beta 2-Microglobulin; Bi | 2000 |
Pamidronate and calcitriol trial for the prevention of early bone loss after renal transplantation.
Topics: Adult; Bone Density; Bone Resorption; Calcitriol; Calcium; Diphosphonates; Female; Humans; Kidney Tr | 2000 |
Effect of pamidronate in preventing local bone loss after total hip arthroplasty: a randomized, double-blind, controlled trial.
Topics: Aged; Alkaline Phosphatase; Amino Acids; Arthroplasty, Replacement, Hip; Biomarkers; Bone Density; B | 2001 |
Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Bone Density; Bone Neoplasms; Bone Resorption; Breast Neop | 2001 |
Effect of pamidronate on skeletal morbidity in myelomatosis. Part 1. The results of the first 12 months of pamidronate therapy.
Topics: Adult; Aged; Bone Resorption; Calcium; Diphosphonates; Female; Humans; Male; Middle Aged; Multiple M | 2000 |
Pamidronate improves the quality of life and induces clinical remission of bone metastases in patients with thyroid cancer.
Topics: Adenocarcinoma, Follicular; Adult; Aged; Analgesics; Anti-Inflammatory Agents; Bone Neoplasms; Bone | 2001 |
Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer.
Topics: Aged; Antineoplastic Agents, Hormonal; Bone Density; Bone Resorption; Diphosphonates; Femur; Gonadot | 2001 |
Pamidronate increases markers of bone formation in patients with multiple myeloma in plateau phase under interferon-alpha treatment.
Topics: Aged; Aged, 80 and over; Alkaline Phosphatase; Antineoplastic Combined Chemotherapy Protocols; beta | 2001 |
Comparison of the effects of intravenous pamidronate and oral clodronate on symptoms and bone resorption in patients with metastatic bone disease.
Topics: Administration, Oral; Adult; Aged; Analgesics, Non-Narcotic; Anti-Inflammatory Agents; Bone Neoplasm | 2001 |
Effects of a single infusion of pamidronate prior to liver transplantation: a bone histomorphometric study.
Topics: Adult; Bone Remodeling; Bone Resorption; Diphosphonates; Female; Humans; Liver Transplantation; Male | 2002 |
Disodium pamidronate identifies differential osteoclastic bone resorption in metastatic prostate cancer.
Topics: Alkaline Phosphatase; Bone Neoplasms; Bone Resorption; Calcium; Creatinine; Diphosphonates; Humans; | 1992 |
Short-term effects of pamidronate on biochemical markers of bone metabolism in osteoporosis--a placebo-controlled dose-finding study.
Topics: Administration, Oral; Aged; Biomarkers; Bone and Bones; Bone Resorption; Diphosphonates; Dose-Respon | 1991 |
Comparison of three intravenous bisphosphonates in cancer-associated hypercalcaemia.
Topics: Administration, Oral; Bone Resorption; Calcium; Clodronic Acid; Diphosphonates; Drug Administration | 1989 |
Aminohydroxypropylidene bisphosphonate (APD) treatment for tumor-associated hypercalcemia: a randomized comparison between a 3-day treatment and single 24-hour infusions.
Topics: Adult; Aged; Bone Resorption; Diphosphonates; Drug Administration Schedule; Female; Hematologic Test | 1989 |
Role of bone and kidney in tumor-induced hypercalcemia and its treatment with bisphosphonate and sodium chloride.
Topics: Adult; Aged; Aged, 80 and over; Bone Resorption; Calcium; Clinical Trials as Topic; Diphosphonates; | 1987 |
150 other studies available for pamidronate and Bone Loss, Osteoclastic
| Article | Year |
|---|---|
Bisphosphonates derived from fatty acids are potent growth inhibitors of Trypanosoma cruzi.
Topics: Animals; Bone Resorption; Diphosphonates; Fatty Acids; Humans; Inhibitory Concentration 50; Parasiti | 2001 |
Inhibition of geranylgeranyl diphosphate synthase by bisphosphonates and diphosphates: a potential route to new bone antiresorption and antiparasitic agents.
Topics: Alkyl and Aryl Transferases; Antiparasitic Agents; Bone Resorption; Diphosphonates; Enzyme Inhibitor | 2002 |
An investigation of bone resorption and Dictyostelium discoideum growth inhibition by bisphosphonate drugs.
Topics: Alkyl and Aryl Transferases; Animals; Bone Resorption; Crystallography, X-Ray; Dictyostelium; Diphos | 2002 |
Highly potent geminal bisphosphonates. From pamidronate disodium (Aredia) to zoledronic acid (Zometa).
Topics: Animals; Bone Resorption; Calcitriol; Diphosphonates; Hypercalcemia; Imidazoles; In Vitro Techniques | 2002 |
Pyridinium-1-yl bisphosphonates are potent inhibitors of farnesyl diphosphate synthase and bone resorption.
Topics: Alkyl and Aryl Transferases; Animals; Antineoplastic Agents; Bone Resorption; Calcium; Dictyostelium | 2005 |
Synthesis, properties, and perspectives of gem-diphosphono substituted-thiazoles.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Bone Density Conservation Agents; Bone Resorption; | 2008 |
Bisphosphonate type-dependent cell viability suppressive effects of carbon nanohorn-calcium phosphate-bisphosphonate nanocomposites.
Topics: Animals; Bone Neoplasms; Bone Resorption; Calcium Phosphates; Carbon; Cell Survival; Diphosphonates; | 2022 |
Updates on Paget's Disease of Bone.
Topics: Bone and Bones; Bone Resorption; Diphosphonates; Humans; Osteitis Deformans; Pamidronate | 2022 |
Hepatic Osteodystrophy: The Mechanism of Bone Loss in Hepatocellular Disease and the Effects of Pamidronate Treatment.
Topics: Animals; Bone and Bones; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone Remodeling | 2017 |
Anti-resorptive effect of pamidronate on extraction socket wall in dogs.
Topics: Alveolar Process; Animals; Bicuspid; Bone Density Conservation Agents; Bone Resorption; Collagen; Do | 2018 |
Sarcoglycans and integrins in bisphosphonate treatment: immunohistochemical and scanning electron microscopy study.
Topics: Bone Neoplasms; Bone Resorption; Calcification, Physiologic; Cell Adhesion; Diphosphonates; Drug-Rel | 2013 |
Effect of bisphosphonates on the rapidly growing male murine skeleton.
Topics: Alendronate; Animals; Apoptosis; Biomechanical Phenomena; Bone and Bones; Bone Development; Bone Res | 2014 |
Comparative effectiveness on survival of zoledronic acid versus pamidronate in multiple myeloma.
Topics: Aged; Bone Density Conservation Agents; Bone Resorption; Cohort Studies; Comparative Effectiveness R | 2015 |
Biomarkers of bone remodeling in multiple myeloma patients to tailor bisphosphonate therapy.
Topics: Aged; Aged, 80 and over; Biomarkers, Tumor; Bone Density Conservation Agents; Bone Remodeling; Bone | 2014 |
INTRAVENOUS PAMIDRONATE IS ASSOCIATED WITH REDUCED MORTALITY IN PATIENTS WITH CHRONIC CRITICAL ILLNESS.
Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Resorption; Chronic Disease; | 2016 |
Dental panoramic indices and fractal dimension measurements in osteogenesis imperfecta children under pamidronate treatment.
Topics: Adolescent; Bone Density; Bone Density Conservation Agents; Bone Resorption; Child; Child, Preschool | 2016 |
Elevated Gα11 expression in osteoblast lineage cells promotes osteoclastogenesis and leads to enhanced trabecular bone accrual in response to pamidronate.
Topics: Absorptiometry, Photon; Angiotensin II; Animals; Bone Density; Bone Density Conservation Agents; Bon | 2016 |
Prophylactic pamidronate partially protects from glucocorticoid-induced bone loss in the mdx mouse model of Duchenne muscular dystrophy.
Topics: Animals; Biomechanical Phenomena; Body Weight; Bone Remodeling; Bone Resorption; Calcification, Phys | 2016 |
Effect of bisphosphonates on vascular calcification and bone metabolism in experimental renal failure.
Topics: Animals; Aortic Diseases; Bone and Bones; Bone Resorption; Calcification, Physiologic; Calcinosis; D | 2009 |
Inhibition of necrotic actions of nitrogen-containing bisphosphonates (NBPs) and their elimination from bone by etidronate (a non-NBP): a proposal for possible utilization of etidronate as a substitution drug for NBPs.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Bone Resorption; Diphosphonates; Ear, Extern | 2010 |
Inhibition of bone resorption blunts osteoarthritis in mice with high bone remodelling.
Topics: ADAM Proteins; Animals; Arthritis, Experimental; Bone Density Conservation Agents; Bone Remodeling; | 2010 |
Breast cancer cells inhibit spontaneous and bisphosphonate-induced osteoclast apoptosis.
Topics: Alendronate; Animals; Apoptosis; Bone Density Conservation Agents; Bone Resorption; Breast Neoplasms | 2011 |
Calcitropic hormones and IGF-I are influenced by dietary protein.
Topics: Animals; Bone and Bones; Bone Resorption; Calcitriol; Calcium; Caseins; Dietary Proteins; Diphosphon | 2011 |
Targeting bone alleviates osteoarthritis in osteopenic mice and modulates cartilage catabolism.
Topics: ADAM Proteins; ADAMTS5 Protein; Animals; Bone and Bones; Bone Diseases, Metabolic; Bone Resorption; | 2012 |
The calcium-binding properties of pamidronate, a bone-resorption inhibitor.
Topics: Bone Resorption; Calcium; Crystallography, X-Ray; Diphosphonates; Humans; Hydrogen Bonding; Models, | 2002 |
Investigation of bone disease using isomerized and racemized fragments of type I collagen.
Topics: Adult; Aged; Biomarkers; Bone Diseases; Bone Neoplasms; Bone Resorption; Cells, Cultured; Collagen; | 2003 |
The effects of intravenous pamidronate on the bone tissue of children and adolescents with osteogenesis imperfecta.
Topics: Adolescent; Bone and Bones; Bone Density; Bone Development; Bone Remodeling; Bone Resorption; Child; | 2002 |
Megakaryoblastic transformation of polycythemia vera with hypercalcemia.
Topics: Adrenocorticotropic Hormone; Bone Resorption; Busulfan; Calcium; Cell Transformation, Neoplastic; Di | 2002 |
A quantitative structure-activity relationship and pharmacophore modeling investigation of aryl-X and heterocyclic bisphosphonates as bone resorption agents.
Topics: Alendronate; Bone Resorption; Diphosphonates; Heterocyclic Compounds; Models, Molecular; Pamidronate | 2003 |
Cellular mechanism of inhibition of osteoclastic resorption of bone and calcified cartilage by long-term pamidronate administration in ovariectomized mature rats.
Topics: Acid Phosphatase; Animals; Apoptosis; Bone Resorption; Calcinosis; Cartilage; Diphosphonates; Dose-R | 2003 |
Staying in bed to benefit ESA's astronauts and Europe's citizens.
Topics: Adaptation, Physiological; Aerospace Medicine; Bed Rest; Body Weight; Bone Density; Bone Resorption; | 2003 |
Bisphosphonates in children with bone diseases.
Topics: Bone Density; Bone Resorption; Child; Diphosphonates; Drug Administration Schedule; Humans; Ibandron | 2003 |
Posterior uveitis: an under-recognized adverse effect of pamidronate: 2 case reports.
Topics: Bone Neoplasms; Bone Resorption; Carcinoma; Conjunctivitis; Diphosphonates; Fatal Outcome; Humans; M | 2003 |
A single bisphosphonate infusion is associated with improved functional capacity in elderly subjects with primary hyperparathyroidism.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Antimetabolites; Bone and Bones; Bone Resorptio | 2003 |
Serum syndecan-1, basic fibroblast growth factor and osteoprotegerin in myeloma patients at diagnosis and during the course of the disease.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; beta 2-Microglobulin | 2004 |
Zoledronate in a patient with pamidronate refractory hypercalcemia syndrome.
Topics: Bone Resorption; Breast Neoplasms; Diphosphonates; Drug Resistance; Female; Humans; Hypercalcemia; I | 2004 |
The bisphosphonate pamidronate on the surface of titanium stimulates bone formation around tibial implants in rats.
Topics: Animals; Bone Resorption; Calcium; Coated Materials, Biocompatible; Diphosphonates; Drug Evaluation, | 2005 |
Delayed osteotomy but not fracture healing in pediatric osteogenesis imperfecta patients receiving pamidronate.
Topics: Absorptiometry, Photon; Adolescent; Anti-Inflammatory Agents; Bone and Bones; Bone Density; Bone Rem | 2004 |
The inhibition of RANKL causes greater suppression of bone resorption and hypercalcemia compared with bisphosphonates in two models of humoral hypercalcemia of malignancy.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Bone Resorption; Calcium; Carrier Proteins; Cell Lin | 2005 |
Bone-specific alkaline phosphatase activity is inhibited by bisphosphonates: role of divalent cations.
Topics: Alendronate; Alkaline Phosphatase; Animals; Bone and Bones; Bone Resorption; Cations, Divalent; Diph | 2005 |
Skeletal retention of bisphosphonate (pamidronate) and its relation to the rate of bone resorption in patients with breast cancer and bone metastases.
Topics: Aged; Alkaline Phosphatase; Bone and Bones; Bone Density Conservation Agents; Bone Neoplasms; Bone R | 2005 |
Case studies in metastatic bone disease: understanding the unique nature of bone loss due to malignancy.
Topics: Aftercare; Bone Neoplasms; Bone Resorption; Calcium; Diphosphonates; Early Diagnosis; Humans; Imidaz | 2006 |
Osteoclast differentiation and bone resorption in multicentric reticulohistiocytosis.
Topics: Adult; Anti-Inflammatory Agents; Arthritis; Bone Resorption; Carrier Proteins; Cell Differentiation; | 2006 |
Pachydermoperiostitis and bisphosphonates.
Topics: Adolescent; Bone Density Conservation Agents; Bone Resorption; Diphosphonates; Disease Progression; | 2006 |
Novel therapeutic agents for bone resorption. Part 1. Synthesis and protonation thermodynamics of poly(amido-amine)s containing bis-phosphonate residues.
Topics: Bone Resorption; Cell Survival; Diphosphonates; Drug Design; Humans; Models, Molecular; Pamidronate; | 2006 |
Inhibition of tooth movement by osteoprotegerin vs. pamidronate under conditions of constant orthodontic force.
Topics: Animals; Apoptosis; Biomechanical Phenomena; Bone Density Conservation Agents; Bone Resorption; Diph | 2007 |
Bisphosphonates can block the deterioration in implant fixation after withdrawal of intermittent doses of parathyroid hormone.
Topics: Animals; Biomechanical Phenomena; Bone Density; Bone Resorption; Bone Screws; Diphosphonates; Drug A | 2008 |
[Treatment of hypercalcemia in osteolytic metastases with oral amino-hydroxypropylidene-diphosphonate].
Topics: Administration, Oral; Adult; Aged; Bone Neoplasms; Bone Resorption; Calcium; Diphosphonates; Female; | 1984 |
Inhibition by diphosphonates of bone resorption induced by the Walker tumor of the rat.
Topics: Animals; Bone and Bones; Bone Resorption; Carcinoma 256, Walker; Clodronic Acid; Diphosphonates; Eti | 1984 |
Kinetic studies of bone and mineral metabolism during treatment with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD) in rats.
Topics: Alkaline Phosphatase; Animals; Bone and Bones; Bone Resorption; Calcification, Physiologic; Calcium; | 1980 |
Regulation of calcium absorption by 1,25,dihydroxy-vitamin D--studies of the effects of a bisphosphonate treatment.
Topics: Aged; Bone Resorption; Calcitriol; Calcium; Diphosphonates; Humans; Hypocalcemia; Middle Aged; Ostei | 1982 |
Efficacy of amino-hydroxypropylidene bisphosphonate in hypercalcemia: observations on regulation of serum calcium.
Topics: Adult; Aged; Bone Resorption; Calcium; Diphosphonates; Female; Humans; Hypercalcemia; Hyperparathyro | 1982 |
Apposition and resorption of bone during oral treatment with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD).
Topics: Administration, Oral; Animals; Anthropometry; Bone and Bones; Bone Development; Bone Resorption; Cal | 1983 |
Differential action of the bisphosphonates (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD) and disodium dichloromethylidene bisphosphonate (Cl2MDP) on rat macrophage-mediated bone resorption in vitro.
Topics: Animals; Binding Sites; Bone Resorption; Calcium; Cell Survival; Diphosphonates; Dose-Response Relat | 1982 |
Pharmacology of disodium (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate.
Topics: Animals; Bone and Bones; Bone Development; Bone Resorption; Calcium; Diphosphonates; Homeostasis; Hy | 1980 |
The effects of bisphosphonates on the resorption cycle of isolated osteoclasts.
Topics: Actins; Animals; Binding Sites; Bone Resorption; Cell Count; Cells, Cultured; Clodronic Acid; Diphos | 1994 |
Hypercalcaemia in primary oxalosis: role of increased bone resorption and effects of treatment with pamidronate.
Topics: Bone Resorption; Calcium Oxalate; Diphosphonates; Humans; Hypercalcemia; Immunohistochemistry; Kidne | 1995 |
Alendronate distributed on bone surfaces inhibits osteoclastic bone resorption in vitro and in experimental hypercalcemia models.
Topics: Alendronate; Animals; Autoradiography; Bone and Bones; Bone Resorption; Calcium; Carbon Radioisotope | 1995 |
Stimulation of bone formation by dynamic mechanical loading of rat caudal vertebrae is not suppressed by 3-amino-1-hydroxypropylidene-1-bisphosphonate (AHPrBP).
Topics: Animals; Body Weight; Bone Development; Bone Resorption; Diphosphonates; Female; Pamidronate; Rats; | 1995 |
Recovery from pamidronate (APD): a two-year study in the dog.
Topics: Animals; Biomechanical Phenomena; Bone and Bones; Bone Density; Bone Resorption; Diphosphonates; Dog | 1994 |
Effects of two novel bisphosphonates on bone cells in vitro.
Topics: Animals; Bone and Bones; Bone Resorption; Breast Neoplasms; Cell Count; Cells, Cultured; Culture Med | 1994 |
The effect of 3-amino-1-hydroxypropylidene-1,1-bisphosphonate (ADP) on the resorptive function of osteoclasts of known nuclear number.
Topics: Animals; Bone Resorption; Cell Nucleus; Cell Size; Cells, Cultured; Chickens; Dentin; Diphosphonates | 1994 |
Long-term elevation of 1,25-dihydroxyvitamin D after short-term intravenous administration of pamidronate (aminohydroxypropylidene bisphosphonate, APD) in Paget's disease of bone.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Bone Resorption; Calcitriol; Calcium; Diphosphonates; Fe | 1994 |
Urinary collagen crosslink excretion: a better index of bone resorption than hydroxyproline in Paget's disease of bone?
Topics: Amino Acids; Biomarkers; Bone Resorption; Calcitonin; Chromatography, High Pressure Liquid; Diphosph | 1993 |
The estrogen antagonist ICI 182,780 reduces cancellous bone volume in female rats.
Topics: Animals; Bone Development; Bone Resorption; Cell Membrane; Diphosphonates; Estradiol; Estrogen Antag | 1993 |
Parenteral pamidronate prevents thyroid hormone-induced bone loss in rats.
Topics: Absorptiometry, Photon; Alkaline Phosphatase; Animals; Body Weight; Bone Density; Bone Resorption; C | 1993 |
Inhibition of 1,25(OH)2D production by hypercalcemia in osteitis fibrosa cystica: influence on parathyroid hormone secretion and hungry bone disease.
Topics: Adenoma; Alkaline Phosphatase; Bone Resorption; Calcitonin; Calcitriol; Calcium; Calcium Carbonate; | 1993 |
Estrogen does not restore bone lost after ovariectomy in the rat.
Topics: Animals; Body Weight; Bone Density; Bone Diseases, Metabolic; Bone Resorption; Calcitonin; Diphospho | 1993 |
Improved treatment of Paget's disease with dimethylaminohydroxypropylidene bisphosphonate.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Bone Resorption; Diphosphonates; Drug Administ | 1993 |
Bisphosphonates act on rat bone resorption through the mediation of osteoblasts.
Topics: Alendronate; Animals; Animals, Newborn; Bone Resorption; Cell Line; Cells, Cultured; Clodronic Acid; | 1993 |
Bisphosphonate (pamidronate/APD) prevents arthritis-induced loss of fracture toughness in the rabbit femoral diaphysis.
Topics: Animals; Arthritis; Bone Resorption; Carrageenan; Diaphyses; Diphosphonates; Dose-Response Relations | 1995 |
Vitamin D intoxication causes hypercalcaemia by increased bone resorption which responds to pamidronate.
Topics: Adrenal Cortex Hormones; Adult; Bone Resorption; Calcium; Diphosphonates; Female; Humans; Hydroxycho | 1995 |
Androgens contribute to the stimulation of cancellous bone formation by ovarian hormones in female rats.
Topics: Animals; Body Weight; Bone and Bones; Bone Resorption; Dihydrotestosterone; Diphosphonates; Female; | 1996 |
Pharmacologic inhibition of particulate-induced bone resorption.
Topics: Analysis of Variance; Animals; Animals, Newborn; Bone Cements; Bone Resorption; Calcitonin; Calcium; | 1996 |
High-dose pamidronate in the management of resistant Paget's disease.
Topics: Aged; Alkaline Phosphatase; Bone Resorption; Diphosphonates; Dose-Response Relationship, Drug; Femal | 1996 |
Bisphosphonates induce apoptosis in mouse macrophage-like cells in vitro by a nitric oxide-independent mechanism.
Topics: Alendronate; Animals; Apoptosis; Bone Marrow; Bone Marrow Cells; Bone Resorption; Cell Division; Cel | 1996 |
Dissociation of binding and antiresorptive properties of hydroxybisphosphonates by substitution of the hydroxyl with an amino group.
Topics: Amines; Analysis of Variance; Animals; Binding Sites; Bone Matrix; Bone Resorption; Calcium Oxalate; | 1996 |
[Effect of low doses of oral pamidronate (APD) on the calcemia of osteopenic or osteoporotic patients].
Topics: Administration, Oral; Analysis of Variance; Bone Diseases, Metabolic; Bone Resorption; Calcium, Diet | 1996 |
Effects of bisphosphonate (pamidronate) on bone resorption resulting from metastasis of a squamous cell carcinoma: report of an autopsy case and evaluation of bone resorbing activity in an experimental animal model.
Topics: Acid Phosphatase; Aged; Animals; Bone Neoplasms; Bone Resorption; Carcinoma, Squamous Cell; Diphosph | 1996 |
Estrogen suppresses activation but enhances formation phase of osteogenic response to mechanical stimulation in rat bone.
Topics: Animals; Bone Development; Bone Resorption; Diphosphonates; Estrogens; Female; Gene Expression Regul | 1996 |
Bisphosphonates in the treatment of bone diseases.
Topics: Bone Neoplasms; Bone Resorption; Breast Neoplasms; Diphosphonates; Disease-Free Survival; Female; Fr | 1996 |
Pamidronate (Aredia).
Topics: Bone Resorption; Diphosphonates; Humans; Hypercalcemia; Osteoclasts; Pamidronate | 1996 |
Pamidronate in the treatment of bone metastases--the European experience.
Topics: Bone Neoplasms; Bone Resorption; Clinical Trials as Topic; Diphosphonates; Europe; Humans; Hypercalc | 1996 |
Pamidronate in the treatment of osteolytic bone lesions in multiple myeloma patients--the American experience.
Topics: Bone Resorption; Clinical Trials as Topic; Diphosphonates; Humans; Multiple Myeloma; Osteoblasts; Pa | 1996 |
Zoledronate: the preclinical pharmacology.
Topics: Animals; Bone Resorption; Cholecalciferol; Depression, Chemical; Diphosphonates; Disease Models, Ani | 1996 |
Comparative evaluation of markers of bone resorption in patients with breast cancer-induced osteolysis before and after bisphosphonate therapy.
Topics: Adult; Aged; Amino Acids; Analysis of Variance; Biomarkers; Bone Neoplasms; Bone Resorption; Breast | 1997 |
In vitro and in vivo effects of tetrakisphosphonates on bone resorption, tumor osteolysis, ectopic calcification, and macrophages.
Topics: Animals; Bioprosthesis; Bone Resorption; Calcinosis; Carcinoma 256, Walker; Cell Line; Cell Survival | 1997 |
Effects of polyethylene on macrophages.
Topics: Animals; Bone Resorption; Calcium Radioisotopes; Cells, Cultured; Culture Media, Conditioned; Dinopr | 1997 |
Treating bone metastases: sparing the patient needless pain.
Topics: Bone Neoplasms; Bone Resorption; Diphosphonates; Humans; Pain; Pain Management; Palliative Care; Pam | 1997 |
Pamidronate content and turnover in sternum, vertebral body, and iliac bones of dogs.
Topics: Animals; Biological Transport, Active; Bone and Bones; Bone Remodeling; Bone Resorption; Diphosphona | 1997 |
Measurement of bone degradation products in serum using antibodies reactive with an isomerized form of an 8 amino acid sequence of the C-telopeptide of type I collagen.
Topics: Adult; Alendronate; Amino Acid Sequence; Antibodies; Biomarkers; Bone Resorption; Collagen; Collagen | 1997 |
Inhibition of bone resorption by pamidronate cannot restore normal gain in cortical bone mass and strength in tail-suspended rapidly growing rats.
Topics: Amino Acids; Animals; Biomechanical Phenomena; Bone Density; Bone Resorption; Diphosphonates; Femur; | 1997 |
Preparation and evaluation of chitosan microspheres containing bisphosphonates.
Topics: Animals; Biocompatible Materials; Bone and Bones; Bone Resorption; Calcinosis; Cattle; Chitin; Chito | 1997 |
Intravenous pamidronate treatment in osteogenesis imperfecta.
Topics: Bone Density; Bone Resorption; Calcium; Child; Child, Preschool; Densitometry; Diphosphonates; Femal | 1997 |
Inhibition of tooth eruption in the rat by a bisphosphonate.
Topics: Acid Phosphatase; Alveolar Process; Animals; Animals, Newborn; Biomarkers; Bone Resorption; Cell Cou | 1998 |
Differential effects of aminosubstituted analogs of hydroxy bisphosphonates on the growth of Dictyostelium discoideum.
Topics: Amines; Animals; Bone Density; Bone Resorption; Dictyostelium; Diphosphonates; Dose-Response Relatio | 1998 |
[Extended use, up to 6 years, of an oral amino-bisphosphonate in patients with established osteoporosis].
Topics: Administration, Oral; Bone Density; Bone Resorption; Diphosphonates; Drug Tolerance; Female; Follow- | 1997 |
Use of pamidronate in chronic and acute bone loss conditions.
Topics: Acute Disease; Bone Density; Bone Resorption; Chronic Disease; Diphosphonates; Female; Humans; Male; | 1997 |
Bisphosphonates and tetracycline: experimental models for their evaluation in calcium-related disorders.
Topics: Alendronate; Animals; Anti-Inflammatory Agents; Betaine; Bone and Bones; Bone Resorption; Calcinosis | 1998 |
Pamidronate corrects the down-regulation of the renal parathyroid hormone (PTH)/PTH-related peptide (PTHrP) receptor mRNA in rats bearing Walker tumors.
Topics: Adenylyl Cyclases; Animals; Anti-Inflammatory Agents; Blotting, Northern; Body Weight; Bone Resorpti | 1998 |
Osteogenic and osteoclastic cell interaction: development of a co-culture system.
Topics: Alkaline Phosphatase; Animals; Bone Resorption; Cell Communication; Cellular Senescence; Chick Embry | 1998 |
Osteoclast-mediated bone resorption is stimulated during short-term administration of granulocyte colony-stimulating factor but is not responsible for hematopoietic progenitor cell mobilization.
Topics: Adult; Amino Acids; Animals; Biomarkers; Bone Resorption; Breast Neoplasms; Calcium; Cell Adhesion; | 1998 |
Prevention of bone loss after heart transplantation with antiresorptive therapy: a pilot study.
Topics: Absorptiometry, Photon; Amino Acids; Biomarkers; Bone Density; Bone Resorption; Calcitriol; Calcium; | 1998 |
Diagnostic and prognostic value of biochemical markers in malignant bone disease: a prospective study on the effect of bisphosphonate on pain intensity and progression of malignant bone disease.
Topics: Aged; Amino Acids; Biomarkers; Bone Density; Bone Neoplasms; Bone Resorption; Chromatography, High P | 1998 |
Bisphosphonates for metastatic bone pain.
Topics: Analgesics, Non-Narcotic; Antineoplastic Agents; Bone Neoplasms; Bone Resorption; Breast Neoplasms; | 1999 |
Nitrogen-containing bisphosphonates inhibit isopentenyl pyrophosphate isomerase/farnesyl pyrophosphate synthase activity with relative potencies corresponding to their antiresorptive potencies in vitro and in vivo.
Topics: Animals; Bone Resorption; Brain; Carbon-Carbon Double Bond Isomerases; Cattle; Clodronic Acid; Dimet | 1999 |
Gamma/delta T-cell stimulation by pamidronate.
Topics: Acute-Phase Reaction; Bone Resorption; Diphosphonates; Humans; Pamidronate; Receptors, Antigen, T-Ce | 1999 |
Assessment of bone response to systemic therapy in an EORTC trial: preliminary experience with the use of collagen cross-link excretion. European Organization for Research and Treatment of Cancer.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Bone Neoplasms; Bone Resorption; Breast Neopl | 1999 |
The development of bone changes induced in rats by recombinant human granulocyte colony-stimulating factor is suppressed by bisphosphonate.
Topics: Animals; Body Weight; Bone Marrow; Bone Resorption; Calcium; Diphosphonates; Femur; Granulocyte Colo | 1999 |
Biphosphonates and the flare phenomenon.
Topics: Antineoplastic Agents; Bone and Bones; Bone Neoplasms; Bone Resorption; Diphosphonates; Humans; Pain | 1999 |
Zoledronate is a potent inhibitor of myeloma cell growth and secretion of IL-6 and MMP-1 by the tumoral environment.
Topics: Antineoplastic Agents; Apoptosis; Bone Marrow Cells; Bone Resorption; Cell Division; Cell Survival; | 1999 |
Effect of growth hormone and pamidronate on bone blood flow, bone mineral and IGF-I levels in the rat.
Topics: Amino Acids; Animals; Body Weight; Bone and Bones; Bone Density; Bone Resorption; Cardiac Output; Di | 2000 |
Pamidronate prevents bone loss associated with carrageenan arthritis by reducing resorptive activity but not recruitment of osteoclasts.
Topics: Animals; Anti-Inflammatory Agents; Arthritis; Bone and Bones; Bone Resorption; Carrageenan; Diphosph | 2000 |
Inhibition of cholesteatomatous bone resorption with pamidronate disodium.
Topics: Animals; Animals, Newborn; Anti-Inflammatory Agents; Bone Resorption; Calcium; Cholesteatoma, Middle | 2001 |
Pamidronate decreases tumor-induced osteoclastogenesis in osteopetrotic mice.
Topics: Animals; Antineoplastic Agents; Apoptosis; Bone Neoplasms; Bone Resorption; Cell Count; Diphosphonat | 2001 |
Bone loss accompanying medical therapies.
Topics: Administration, Inhalation; Antineoplastic Agents, Hormonal; Bone Density; Bone Resorption; Diphosph | 2001 |
A pharmacokinetic and pharmacodynamic model for intravenous bisphosphonate (pamidronate) in osteoporosis.
Topics: Adult; Aged; Bone Resorption; Diphosphonates; Female; Humans; Hydroxyproline; Male; Middle Aged; Mod | 2002 |
Combined calcitriol-pamidronate therapy for bone hyperresorption in spinal cord injury.
Topics: Administration, Oral; Adolescent; Adult; Aged; Bone Remodeling; Bone Resorption; Calcitriol; Calcium | 2001 |
Generation and activity of equine osteoclasts in vitro: effects of the bisphosphonate pamidronate (APD).
Topics: Acid Phosphatase; Animals; Bone Marrow; Bone Resorption; Calcium Phosphates; Cell Death; Cells, Cult | 2002 |
Inhibitory action of bisphosphonates on bone resorption does not involve the regulation of RANKL and OPG expression.
Topics: Alendronate; Animals; Bone Resorption; Carrier Proteins; Cells, Cultured; Diphosphonates; Gene Expre | 2002 |
Measurement of serum [3H]tetracycline kinetics and indices of kidney function facilitate study of the activity and toxic effects of bisphosphonates in bone resorption.
Topics: Alkaline Phosphatase; Animals; Body Weight; Bone and Bones; Bone Resorption; Diphosphonates; Femur; | 1992 |
The anabolic action of 17 beta-estradiol (E2) on rat trabecular bone is suppressed by (3-amino-1-hydroxypropylidene)-1-bisphosphonate (AHPrBP).
Topics: Animals; Body Weight; Bone and Bones; Bone Development; Bone Resorption; Diphosphonates; Estradiol; | 1992 |
Disodium 1-hydroxy-3-(1-pyrrolidinyl)-propylidene-1,1-bisphosphonate (EB-1053) is a potent inhibitor of bone resorption in vitro and in vivo.
Topics: Acid Phosphatase; Animals; Bone Density; Bone Resorption; Calcium; Cells, Cultured; Diphosphonates; | 1992 |
Treatment of resistant tumor-induced hypercalcemia with escalating doses of pamidronate (APD).
Topics: Bone Resorption; Diphosphonates; Drug Resistance; Female; Humans; Hypercalcemia; Middle Aged; Neopla | 1992 |
Preliminary results of the use of urinary excretion of pyridinium crosslinks for monitoring metastatic bone disease.
Topics: Administration, Oral; Adult; Amino Acids; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Calcium | 1992 |
Estrogen maintains trabecular bone volume in rats not only by suppression of bone resorption but also by stimulation of bone formation.
Topics: Animals; Bone Resorption; Diphosphonates; Disease Models, Animal; Estradiol; Female; Osteogenesis; O | 1992 |
Pamidronate reduces PTH-mediated bone loss in a gene transfer model of hyperparathyroidism in rats.
Topics: Absorptiometry, Photon; Animals; Bone Density; Bone Resorption; Diphosphonates; Hyperparathyroidism; | 1991 |
Treatment of bone metastases from breast cancer and myeloma with pamidronate.
Topics: Adult; Aged; Aged, 80 and over; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Diphosphonates; D | 1991 |
BM 21.0955, a potent new bisphosphonate to inhibit bone resorption.
Topics: Alendronate; Animals; Benzoates; Bone Resorption; Calcium; Clodronic Acid; Diphosphonates; Etidronic | 1991 |
Modulation of PTH-stimulated osteoclastic resorption by bisphosphonates in fetal mouse bone explants.
Topics: Animals; Bone Resorption; Calcium; Clodronic Acid; Culture Techniques; Diphosphonates; Dose-Response | 1991 |
Inhibition of bone resorption by bisphosphonates: interactions between bisphosphonates, osteoclasts, and bone.
Topics: Animals; Bone and Bones; Bone Marrow Cells; Bone Resorption; Calcitonin; Cells, Cultured; Clodronic | 1991 |
Effect of a single infusion of aminohydroxypropylidene on calcium and bone metabolism in healthy volunteers monitored during 2 months.
Topics: 24,25-Dihydroxyvitamin D 3; Adult; Alkaline Phosphatase; Bone and Bones; Bone Development; Bone Reso | 1991 |
The role of 1,25-dihydroxyvitamin D in the maintenance of hypercalcemia in a patient with an ovarian carcinoma producing parathyroid hormone-related protein.
Topics: Aged; Bone Resorption; Calcitriol; Calcium; Diphosphonates; Female; Humans; Hypercalcemia; Ovarian N | 1991 |
Bisphosphonates directly inhibit the bone resorption activity of isolated avian osteoclasts in vitro.
Topics: Animals; Bone Resorption; Cells, Cultured; Chickens; Diphosphonates; Etidronic Acid; Female; Osteocl | 1990 |
Effects of bisphosphonates on isolated rat osteoclasts as examined by reflected light microscopy.
Topics: Alendronate; Animals; Bone Resorption; Cattle; Cell Survival; Diphosphonates; Etidronic Acid; In Vit | 1990 |
[Establishment of a model to evaluate inhibition of bone resorption induced by bladder tumor (MBT-2) in mice].
Topics: Animals; Bone Neoplasms; Bone Resorption; Diphosphonates; Disease Models, Animal; Female; Mice; Neop | 1990 |
Short-term metabolic effects of pamidronate in patients with prostatic carcinoma and bone metastases.
Topics: Bone and Bones; Bone Neoplasms; Bone Resorption; Calcium; Diphosphonates; Humans; Male; Pamidronate; | 1989 |
[A single infusion of Pamidronate (APD) in Paget's disease of bone].
Topics: Aged; Aged, 80 and over; Alkaline Phosphatase; Bone Resorption; Diphosphonates; Female; Humans; Hydr | 1989 |
Application of an in vitro model and a clinical protocol in the assessment of the potency of a new bisphosphonate.
Topics: Administration, Oral; Aged; Animals; Bone and Bones; Bone Resorption; Clinical Protocols; Diphosphon | 1989 |
Bisphosphonates can reduce osteoclastic bone resorption by two different mechanisms.
Topics: Animals; Bone and Bones; Bone Resorption; Cell Differentiation; Chemotaxis; Clodronic Acid; Culture | 1986 |
Effects of four bisphosphonates on bone resorption, lysosomal enzyme release, protein synthesis and mitotic activities in mouse calvarial bones in vitro.
Topics: Animals; Bone and Bones; Bone Resorption; Clodronic Acid; Diphosphonates; Etidronic Acid; In Vitro T | 1987 |
Bisphosphonates and bone resorption: effects on collagenase and lysosomal enzyme excretion.
Topics: Acetylglucosaminidase; Animals; Bone Resorption; Calcium; Clodronic Acid; Depression, Chemical; Diph | 1985 |
New inhibitors of osteolysis: implications for hypercalcemia and bone metastases.
Topics: Amifostine; Bone Neoplasms; Bone Resorption; Clodronic Acid; Diphosphonates; Humans; Hypercalcemia; | 1986 |
The effects of hydrocortisone, parathyroid hormone and the bisphosphonate, APD, on bone resorption in neonatal mouse calvaria.
Topics: Animals; Animals, Newborn; Bone and Bones; Bone Resorption; Calcium; Diphosphonates; DNA; Drug Inter | 1986 |
Treatment of cancer associated hypercalcaemia with combined aminohydroxypropylidene diphosphonate and calcitonin.
Topics: Bone Resorption; Calcitonin; Calcium; Creatinine; Diphosphonates; Drug Therapy, Combination; Humans; | 1986 |
Different schedules of administration of (3 amino-1-hydroxypropylidene)-1, 1 bisphosphonate induce different changes in pig bone remodeling.
Topics: Animals; Bone Resorption; Diphosphonates; Drug Administration Schedule; Osteoblasts; Osteoclasts; Os | 1987 |
Diphosphonates for otospongiosis.
Topics: Adult; Bone Development; Bone Resorption; Clodronic Acid; Diphosphonates; Etidronic Acid; Humans; Ma | 1985 |
Enhancement of the inhibitory action of APD on the transformation of osteoclast precursors into resorbing cells after dimethylation of the amino group.
Topics: Animals; Bone Resorption; Diphosphonates; Methylation; Mice; Osteoclasts; Pamidronate; Parathyroid H | 1987 |
Inhibition by aminohydroxypropylidene bisphosphonate (AHPrBP) of 1,25(OH)2 vitamin D3-induced stimulated bone turnover in the mouse.
Topics: Alkaline Phosphatase; Animals; Bone and Bones; Bone Development; Bone Matrix; Bone Resorption; Calci | 1985 |
Inhibition of bone matrix apposition by (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (AHPrBP) in the mouse.
Topics: Acid Phosphatase; Animals; Body Weight; Bone Development; Bone Matrix; Bone Resorption; Calcium; Dip | 1985 |